Document:

<PAGE>

Exhibit 10.33

                           MARKETING LICENSE AGREEMENT

         This Marketing License Agreement (the "Agreement") made and entered
into as of this 4th day of June, 2002 (the "Effective Date") is by and among
Columbia Laboratories (Bermuda) Limited, a Bermuda corporation with its
principal place of business at Rosebank Center, 14 Bermudiana Road, Pembroke,
HM08 Bermuda ("Columbia Bermuda"), Columbia Laboratories, Inc., a Delaware
corporation with its principal place of business at 220 South Orange Avenue,
Livingston, New Jersey 07039 ("Columbia"), Ares Trading S.A., a Swiss company
with its principal place of business at Chateau de Vaumarcus, 2028 Vaumarcus,
Switzerland ("Ares") and Serono, Inc., a Delaware corporation with its principal
place of business at One Technology Place, Rockland, Massachusetts 02370
("Serono").

                                   WITNESSETH:

         WHEREAS, Ares and Columbia Bermuda entered into a License and Supply
Agreement as of May 20, 1999, under which Columbia Bermuda granted to Ares a
license to certain Patents and Technology related to the Product, including the
exclusive right and license, with the right to sublicense, under such Patents
and Technology to market, use and sell the Product in the Territory, and
Columbia Bermuda agreed to manufacture and sell to Ares the Product (as such
terms are defined in the License and Supply Agreement);

         WHEREAS, Ares has appointed Serono as the exclusive distributor of the
Product in the United States, subject to the terms of the License and Supply
Agreement; and

         WHEREAS, Serono desires to grant to Columbia an exclusive license,
subject to the terms of the License and Supply Agreement including, without
limitation, Section 2(h) thereof, to Promote and sell the Product in the United
States (as hereinafter defined) to the Non-Fertility Specialist Market (as
hereinafter defined), and Columbia desires to receive such exclusive license, on
the terms and subject to the conditions set forth herein.

         NOW, THEREFORE, for and in consideration of the mutual premises and
covenants herein contained, the parties hereto agree as follows.

         1.       Definitions. As used in this Agreement, the following terms
shall have the respective meanings set forth below:

                  (a)     "Affiliate" shall mean any corporation or other
         business entity that either directly or indirectly controls a party to
         this Agreement, is controlled by such party, or is under common control
         of such party. As used herein, the term "control" means possession of
         the power to direct or cause the direction of the management and
         policies of a corporation or other entity whether through the ownership
         of voting securities, by contract or otherwise.

    [***] A CONFIDENTIAL PORTION OF THE MATERIAL HAS BEEN OMITTED AND FILED
             SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.

<PAGE>

                  (b)     "AHPC" shall mean Wyeth (formerly American Home
         Products Corporation) of Five Giralda Farms, Madison, New Jersey
         07940-0874, a Delaware corporation, represented by its Wyeth-Ayerst
         Laboratories Division.

                  (c)     "Ares' Net Sales" shall have the meaning attributed to
         "Net Sales" under the License and Supply Agreement.

                  (d)     "Assignment Agreement" shall mean the Assignment and
         Royalty Agreement dated as of May 27, 1999, as amended, by and between
         AHPC and Ares.

                  (e)     "Columbia's Net Sales" shall mean the aggregate
         equivalent of gross revenue received by Columbia, its Affiliates and
         sublicensees from or on account of the sale of the Product under this
         Agreement to non-affiliated third parties, less (i) reasonable credits
         or allowances, if any, actually granted on account of cash or trade
         discounts, recalls, rebates, rejection or return of the Product
         previously sold, (ii) excises, sales taxes, value added taxes,
         consumption taxes, duties or other taxes imposed upon and paid with
         respect to such sales (excluding income or franchise taxes of any kind)
         and (iii) separately itemized insurance and transportation costs
         incurred in shipping the Product to such third parties. No deduction
         shall be made for any item of cost incurred by Columbia, its Affiliates
         or sublicensees in preparing, manufacturing, shipping or selling the
         Product except as permitted pursuant to clauses (i), (ii) or (iii) of
         the foregoing sentence. Columbia's Net Sales shall not include any
         transfer between Columbia and any of its Affiliates or sublicensees for
         resale. No transfer of the Product for test or development purposes or
         as free samples shall be considered a sale hereunder for accounting or
         payment purposes. For the avoidance of doubt and for the purposes of
         this definition (i) Ares shall not be deemed to be a sublicensee of
         Columbia, and (ii) the sale, license or other transfer to an Affiliate
         or sublicensee shall not be considered a sale hereunder for accounting
         or payment purposes. Notwithstanding the foregoing, Columbia's Net
         Sales of Products that are dispensed to patients within the Fertility
         Specialist Market shall be calculated in the manner set forth in
         Exhibit B.

                  (f)     "Confidential Information" shall mean all information
         and/or technical data which is disclosed by one party hereto pursuant
         to this Agreement which the disclosing party treats as confidential and
         identifies as such, other than information (i) known to the receiving
         party or its Affiliates prior to the disclosure of such information to
         such party, provided said prior knowledge is supportable by documentary
         evidence, (ii) which at the time of the disclosure is, or thereafter
         becomes, generally known to the public, provided that such public
         knowledge does not result from any act or disclosure by the receiving
         party or any of its Affiliates in violation of the terms of this
         Agreement, (iii) which can be shown to be independently discovered,
         after the date hereof, by a party, or any of its Affiliates, without
         the aid, application or use of the disclosed information, or (iv)
         obtained by the receiving party from a third party which is determined
         to be in lawful possession of such information, provided such third
         party is not in violation of any contractual or legal obligation to the
         disclosing party or any of its Affiliates with respect to such
         information. Confidential Information of Ares and Serono shall be
         deemed to include Dispensing Data disclosed by either one of them to
         Columbia or Columbia Bermuda, regardless of whether such Dispensing
         Data is identified as

    [***] A CONFIDENTIAL PORTION OF THE MATERIAL HAS BEEN OMITTED AND FILED
             SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.

                                     - 2 -

<PAGE>

         confidential. Confidential Information of Columbia and Columbia Bermuda
         shall be deemed to include Dispensing Data disclosed by either one of
         them to Ares or Serono regardless of whether such Dispensing Data is
         identified as confidential.

                  (g)     "Dispensing Data" shall mean Non-Retail Data and
         Prescriber Data.

                  (h)     "FDA" shall mean the U.S. Food and Drug
         Administration.

                  (i)     "Fertility Specialist Market" shall mean (i) all
         reproductive endocrinologists in the United States and their patients;
         and (ii) all other physicians in the United States, including
         obstetricians and gynecologists, who use Injectable Gonadotropins to
         treat infertility or who are associated with an infertility treatment
         center and their patients. Serono and Columbia shall agree in writing
         to a list of the reproductive endocrinologists and other physicians who
         they have determined are within the Fertility Specialist Market as of
         the Effective Date (the "Physician List"). No more than once each year
         during the Term of this Agreement beginning on the first anniversary of
         the Effective Date, Serono shall consider, at the request of Columbia,
         removing from the Physician List physicians in the United States (i)
         who are not reproductive endocrinologists, (ii) who are not associated
         with an infertility treatment center and (iii) who Columbia
         demonstrates prescribed less than $[***] of Injectable Gonadotropins in
         the preceding year. Serono shall consider removing such physicians from
         the Physician List in good faith giving primary consideration to its
         own business interests. Serono shall have the right to remove from the
         Physician List any physician upon prior notice to Columbia. Serono
         shall have the right to add to the Physician List reproductive
         endocrinologists in the United States and other physicians in the
         United States, including obstetricians and gynecologists, who use
         Injectable Gonadotropins to treat infertility or who are associated
         with an infertility treatment center, provided that Serono shall notify
         Columbia, Columbia shall have fifteen (15) days thereafter to provide
         comments to Serono regarding such additions, and Serono shall consider
         such comments in good faith giving primary consideration to its own
         business interests.

                  (j)     "Injectable Gonadotropins" shall mean follicle
         stimulating hormone, human menopausal gonadotropin, human chorionic
         gonadotropin, gonadotropin releasing hormone and luteinizing hormone.

                  (k)     "License and Supply Agreement" shall mean the License
         and Supply Agreement dated as of May 20, 1999, by and between Columbia
         Bermuda and Ares, as amended and restated by that certain Amended and
         Restated License and Supply Agreement dated as of the date hereof and
         as further amended in writing and from time to time by agreement of the
         parties.

                  (l)     "Non-Fertility Specialist Market" shall mean
         individual obstetricians, gynecologists and primary care physicians
         located in the United States and their nurses, staff and patients, but
         excluding the Fertility Specialist Market.

    [***] A CONFIDENTIAL PORTION OF THE MATERIAL HAS BEEN OMITTED AND FILED
             SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.

                                     - 3 -

<PAGE>

                  (m)     "Non-Retail Data" shall mean data acquired by Serono
         from objective, reliable third parties regarding the sale of Product by
         wholesalers to non-retail dispensing organizations, such as [***].

                  (n)     "Patents" shall have the meaning set forth in the
         License and Supply Agreement.

                  (o)     "Prescriber Data" shall mean data acquired by Serono
         (i) from objective, reliable third parties regarding the dispensing of
         the Product from pharmacies to patients and reported by physician name,
         such as [***], and (ii) directly from pharmacies regarding the
         dispensing of the Product to patients and reported by physician name,
         which is not included in the data described in Subsection (o)(i).

                  (p)     "Product" shall mean Product A and Product B.

                  (q)     "Product A" shall mean progesterone/COL-1620 vaginal
         gel containing progesterone in a concentration of four percent (4%).

                  (r)     "Product B" shall mean progesterone/COL-1620 vaginal
         gel containing progesterone in a concentration of eight percent (8%).

                  (s)     "Promote" and "Promotional" shall mean, with respect
         to the Product, any activities undertaken by or on behalf of a party to
         encourage sales or use of the Product, including, without limitation,
         sales detail calls, product sampling, journal advertising, direct mail
         programs, direct-to-consumer advertising, convention exhibits and all
         other forms of marketing, advertising or promotion.

                  (t)     "Technology" shall have the meaning set forth in the
         License and Supply Agreement.

                  (u)     "Territory" shall have the meaning set forth in the
         License and Supply Agreement.

                  (v)     "Unit" shall mean a single applicator.

                  (w)     "United States" shall mean the several United States,
         the District of Columbia and Puerto Rico.

         2.       Grant of License.
                  ----------------

                  (a)     Subject to the License and Supply Agreement,
         including, without limitation, Ares' right under Section 2(h) thereof
         to Promote the Product to the Non-Fertility Specialist Market in the
         United States to the extent that such Promotional activities are
         incidental to its Promotional efforts to the Fertility Specialist
         Market, Serono hereby grants to Columbia, and Columbia accepts from
         Serono, on the terms and conditions stated herein, the exclusive right
         and license, with the right to sublicense as set forth in Section 2(b),
         under the Patents and Technology to (i) Promote the Product in the
         United States to the Non-Fertility Specialist Market as permitted under
         applicable law

    [***] A CONFIDENTIAL PORTION OF THE MATERIAL HAS BEEN OMITTED AND FILED
             SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.

                                     - 4 -

<PAGE>

         and (ii) sell the Product in the United States for any indication or
         indications permitted under applicable law.

                  (b)     Columbia shall have the right to sublicense its rights
         under Section 2(a) to Columbia's Affiliates and, pursuant to Section
         2(c), to third parties. Each sublicense granted by Columbia pursuant to
         the terms of this Agreement shall be in writing and shall include
         provisions restricting the Promotional and sales activities of such
         sublicensee to the same extent Columbia is restricted under this
         Agreement and granting Serono and Ares third-party beneficiary status
         under the sublicense. Columbia shall notify Serono and Ares of any
         default of such sublicense and shall be liable to Serono and Ares for
         any action or inaction of such sublicensees that would violate this
         Agreement as if the action or inaction were that of Columbia directly.

                  (c)     Columbia may employ a contract sales force or other
         third party for the purpose of Promoting the Product on behalf of
         Columbia in accordance with this Agreement, provided that such sales
         force or other third party does not promote any product that competes
         with infertility products offered by Serono at the time Columbia
         establishes the relationship with such contract sales force or other
         third party.

                  (d)     Columbia shall not seek to register or permit any
         third party to register the Product outside of the United Sates for
         sale, and will not permit any third party to resell the Product sold by
         Columbia under this Agreement outside of the United States.

                  (e)     Neither Ares nor Serono shall grant to any Affiliates,
         licensees, sublicensees, or any third party any rights and/or licenses
         granted to Columbia herein. Ares retains all rights under the Patents
         and Technology in the Territory granted to it under the License and
         Supply Agreement and not granted by Serono to Columbia hereunder,
         including, without limitation, the right under the Patents and
         Technology while the License and Supply Agreement is in effect to (i)
         Promote the Product to the Fertility Specialist Market, and (ii) sell
         the Product.

         3.       Columbia's Marketing and Distribution Obligations.
                  -------------------------------------------------

                  (a)     Columbia may Promote the Product in the United States
         to the Non-Fertility Specialist Market pursuant to Section 2 hereof,
         and sell the Product in the United States. In furtherance and not in
         limitation of the foregoing, Columbia shall not, directly or
         indirectly, Promote, or engage third parties to Promote the Product to
         the Fertility Specialist Market. Notwithstanding the foregoing,
         Columbia shall be permitted to Promote the Product to the Fertility
         Specialist Market to the extent that such Promotional activities are
         incidental to Promotional efforts in the United States to the
         Non-Fertility Specialist Market.

                  (b)     Subject to the other terms of this Agreement including
         the special termination right of Serono in Section 10(c), Columbia may
         sell the Product in the United States by distributing the Product
         through all distribution channels including, without limitation,
         managed care, chain pharmacies, wholesalers and independent pharmacies
         on terms and conditions established by Columbia in its sole discretion.

    [***] A CONFIDENTIAL PORTION OF THE MATERIAL HAS BEEN OMITTED AND FILED
             SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.

                                     - 5 -

<PAGE>

                  (c)     Columbia shall Promote and sell the Product in
         association with the trademark PROCHIEVEtm or other trademark (the
         "Columbia Mark") and trade dress that are wholly different from the
         CRINONE mark and the trade dress currently used by Serono and its
         Affiliates in association with the Product. An example of the trade
         dress currently used by Serono in association with the Product is
         displayed in Exhibit A. Serono acknowledges that the applicator and the
         dimensions of the packaging for the Product sold by Columbia may be the
         same as that for the Product sold by Serono.

                  (d)     Columbia's Promotional materials, presentations and
         sales calls to the Non-Fertility Specialist Market for Product B shall
         deliver a sustained, consistent message that any patient who has not
         become pregnant after three (3) cycles of treatment using clomiphene
         citrate together with Product B should seek care of an assisted
         reproduction technology specialist for further treatment. In order for
         Serono to verify compliance by Columbia with this Section 3(d) and its
         other obligations under this Agreement, Columbia shall, upon the
         reasonable written request of Serono, but not more than once per
         calendar quarter (i) identify to Serono physicians, nurses and staff
         within the Non-Fertility Specialist Market; and (ii) provide Serono
         with copies of any communications, including communications sent
         electronically, as disseminated by Columbia regarding Product B.

                  (e)     Columbia shall not Promote or market the Product by
         comparison or reference to the Product as sold by Serono and its
         Affiliates and shall not reference the CRINONE mark in Promotional
         materials, provided, however, that Columbia may respond truthfully to
         unsolicited inquiries regarding the Product and the Product as sold by
         Serono.

                  (f)     Notwithstanding anything contained in this Agreement
         to the contrary, Columbia may refer to, and otherwise use, all
         published and unpublished studies regarding the Product in its
         Promotional efforts to the Non-Fertility Specialist Market within the
         United States, including reference to the CRINONE mark to the extent it
         is used to identify the studies.

                  (g)     Columbia shall provide quarterly sales and other
         marketing information useful to Serono in monitoring Columbia's sales
         progress.

                  (h)     Columbia shall be responsible for receiving and
         responding to complaints and requests for information from patients and
         others regarding the Product sold by Columbia. Within thirty (30) days
         following the end of each calendar month during the term of this
         Agreement, Columbia shall provide to Serono a written report detailing
         complaints regarding the Product received during such month, provided
         that Columbia shall notify Serono of any serious adverse events within
         two (2) days following notice to Columbia of such serious adverse
         events.

         4.       Columbia's Obligations Regarding License and Supply Agreement.
Columbia shall supply to Ares under the terms of the License and Supply
Agreement all of Ares requirements of the Product in accordance with Section
4(j) of the License and Supply Agreement before supplying its own requirements.
Columbia shall not take any action that could

    [***] A CONFIDENTIAL PORTION OF THE MATERIAL HAS BEEN OMITTED AND FILED
             SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.

                                     - 6 -

<PAGE>

reasonably be expected to adversely affect Ares' rights under the License and
Supply Agreement or Columbia's ability to perform fully its obligations
thereunder.

         5.       Compensation.
                  ------------

                  (a)     Royalties.

                          (i)    Amount. Columbia shall pay to Serono a royalty
                  of thirty percent (30%) of Columbia's Net Sales of Products
                  provided that Columbia shall pay an additional amount equal to
                  forty percent (40%) (but not to exceed seventy percent (70%)
                  in total) of Columbia's Net Sales of Products that are
                  dispensed to patients within the Fertility Specialist Market.

                          (ii)   Reports and Payments. Within forty-five (45)
                  days following each calendar quarter during the Term, Columbia
                  shall (a) provide to Serono a written report, in such detail
                  as Serono may reasonably require, showing (i) the description
                  and number of all Units of the Product sold by Columbia and
                  its sublicensees during such calendar quarter, the number of
                  free samples of the Product distributed by Columbia and its
                  sublicensees, and the number of any returns of the Product
                  made during such calendar quarter, and (ii) Columbia's Net
                  Sales of the Product sold during such calendar quarter; and
                  (b) pay to Serono 30% of such Net Sales in immediately
                  available funds by wire transfer to an account designated by
                  Serono. If no amount is due for such calendar quarter, a
                  written statement to that effect shall be furnished.

                          (iii)  Determination of Market. With respect to each
                  quarter during the term, Serono shall determine based on the
                  Dispensing Data and report to Columbia in writing in the form
                  set forth in Exhibit B (a) the number of Units of Products
                  sold by Columbia and dispensed to patients within the
                  Non-Fertility Specialist Market and the Fertility Specialist
                  Market, (b) Columbia's Net Sales of Product dispensed to
                  patients within the Non-Fertility Specialist Market and the
                  Fertility Specialist Market, and (c) the number of Units of
                  Products sold by Serono and dispensed to patients within the
                  Non-Fertility Specialist Market in the United States and the
                  Fertility Specialist Market. Within forty-five (45) days
                  following receipt of such report, Columbia shall pay to Serono
                  in immediately available funds by wire transfer to an account
                  designated by Serono an additional royalty of 40% of
                  Columbia's Net Sales of all Products sold by Columbia and
                  dispensed to patients within the Fertility Specialist Market.
                  In the event that, within fifteen (15) business days following
                  receipt of such report, Columbia notifies Serono in writing
                  that Columbia disagrees with such determination and report,
                  and Columbia provides written documentation supporting such
                  disagreement, then Serono and Columbia shall refer the matter
                  to an independent expert in pharmaceutical product marketing
                  jointly selected by each of the parties (the "Expert") and, if
                  the parties cannot agree on an Expert, they shall thereafter
                  request the American Arbitration Association ("AAA"), sitting
                  in the City of New York, to select an Expert within thirty
                  (30) days following receipt of such request. In each case, the
                  Expert shall be selected having regard to his or her
                  suitability to

    [***] A CONFIDENTIAL PORTION OF THE MATERIAL HAS BEEN OMITTED AND FILED
             SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.

                                     - 7 -

<PAGE>

                  determine the particular dispute or difference. Unless
                  otherwise agreed between Serono and Columbia, the following
                  rules shall apply to the appointment of the Expert. Serono and
                  Columbia shall share the fees of the AAA and the Expert
                  equally. The Expert shall be entitled to inspect and examine
                  all documentation and any other material that the Expert may
                  consider to be relevant to the dispute. The Expert shall
                  afford each party a reasonable opportunity (in writing or
                  orally) for stating reasons in support of such contentions as
                  each party may wish to make relative to the matters under
                  consideration. The Expert shall give notice in writing of his
                  or her determination to the parties within such time as may be
                  stipulated in his terms of appointment or in the absence of
                  such stipulation, as soon as practicable, but in any event
                  within forty-five (45) days from the reference of the dispute
                  or difference.

                          (iv)   Post-Termination Report and Payment. Columbia
                  shall provide to Serono a written report within forty-five
                  (45) days following the date of any termination of this
                  Agreement, in such detail as Serono may reasonably require,
                  showing the items set forth in Section 5(a)(ii) above for
                  sales of the Product that were not previously reported to
                  Serono, and shall pay to Serono all amounts that such report
                  shows are due and that are subsequently determined to be due
                  under Section 5(a)(iii) in immediately available funds by wire
                  transfer to an account designated by Serono.

                  (b)     Contribution to Royalties on Sales of Product B over
         $[***]. In the event that, for any calendar year or other period, Ares
         is required to pay to AHPC royalties under the Assignment and Royalty
         Agreement on sales of Product B in excess of $[***], then (i) Ares
         shall provide to Columbia a copy of the written report with regard to
         such calendar year or other period furnished by Ares to AHPC under the
         Assignment and Royalty Agreement, which report shall include the
         description and number of all Units of Product B sold by Ares and its
         Affiliates (including Serono) and its sublicensees (including Columbia)
         during such calendar year or other period and the royalties payable
         thereon by Ares to AHPC; and (ii) Columbia shall, within thirty (30)
         days following receipt of such report, pay to Ares an amount calculated
         by multiplying the royalties payable by Ares to AHPC for such calendar
         year or other period by the fraction X/Y where X is Columbia's Net
         Sales of Product B in the United States during such calendar year or
         other period and Y is Columbia's Net Sales of Product B in the United
         States plus Ares' Net Sales of Product B throughout the world during
         such calendar year or other period. Such payment shall be made in
         immediately available funds by wire transfer to an account designated
         by Ares.

                  (c)     Currency. All amounts under this Agreement are in
         United States Dollars.

                  (d)     No Implication of Right to Sell to Fertility
         Specialist Market. Although Columbia is obligated under the terms of
         this Section 5 to pay a higher royalty rate for Columbia's Net Sales of
         Product dispensed to patients within the Fertility Specialist Market,
         nothing in this Section 5 shall be deemed to grant to Columbia,
         directly or indirectly, a license to Promote or engage third parties to
         Promote the Product to the

    [***] A CONFIDENTIAL PORTION OF THE MATERIAL HAS BEEN OMITTED AND FILED
             SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.

                                     - 8 -

<PAGE>

         Fertility Specialist Market or be deemed to limit Serono's right to
         terminate this Agreement pursuant to Section 10(c).

         6.       Confidentiality.
                  ---------------

         Each party hereto shall hold all Confidential Information in
confidence, use it only in connection with the performance of its obligations
pursuant to this Agreement and use its diligence efforts (consistent with those
which it uses to safeguard its own confidential information) to safeguard
Confidential Information and to prevent the unauthorized use or disclosure of
any Confidential Information. Each party hereto shall ensure that its Affiliates
or employees who have access to any Confidential Information shall be made aware
of and subject to these obligations. The receiving party may disclose
Confidential Information to individuals who have a need to know in order for the
receiving party to perform its obligations or enjoy its rights under this
Agreement, provided that each such individual is bound by a confidentiality
obligation comparable to the obligation set forth in this Section 6. The
obligations of the parties hereto under this Section 6 shall survive for five
(5) years after the expiration or termination of this Agreement.

         7.       Representations, Warranties and Covenants and Indemnification.
                  -------------------------------------------------------------

                  (a)     Ares and Serono each hereby represents, warrants and
         covenants the following:

                          (i)    It is a corporation duly organized, existing
and in good standing under the laws of the place of its organization, with full
right, power and authority to enter into and perform this Agreement.

                          (ii)   The execution, delivery and performance of this
Agreement do not conflict with, violate or breach any agreement to which it is a
party, or its articles of incorporation or bylaws.

                          (iii)  This Agreement has been duly executed and
delivered by it and is a legal, valid and binding obligation enforceable against
it in accordance with its terms.

                          (iv)   It shall comply with all applicable laws,
consent decrees and regulations of any federal, state or other governmental
authority in performing this Agreement.

                  (b)     Columbia and Columbia Bermuda each hereby represents,
         warrants and covenants the following:

                          (i)    It is a corporation duly organized, existing
and in good standing under the laws of the place of its organization, with full
right, power and authority to enter into and perform this Agreement.

    [***] A CONFIDENTIAL PORTION OF THE MATERIAL HAS BEEN OMITTED AND FILED
             SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.

                                     - 9 -

<PAGE>

                          (ii)   The execution, delivery and performance of this
Agreement do not conflict with, violate or breach any agreement to which it is a
party, or its articles of organization or bylaws.

                          (iii)  This Agreement has been duly executed and
delivered by it and is a legal, valid and binding obligation enforceable against
it in accordance with its terms.

                          (iv)   It shall comply with all applicable laws,
consent decrees and regulations of any federal, state or other governmental
authority in performing this Agreement.

                  (c)     Indemnification.

                          (i)    Serono agrees to indemnify and hold harmless
Columbia, its Affiliates and sublicensees and their respective employees,
agents, officers and directors from and against any claims, losses, liabilities,
damages, costs and expenses (including reasonable attorneys' fees) incurred by
Columbia, its Affiliates or sublicensees arising out of or in connection with
any (A) breach by Ares or Serono of any representation, warranty, covenant or
obligation hereunder, or (B) intentional or negligent act or omission on the
part of Ares or Serono or any of its employees or agents in the performance of
this Agreement.

                          (ii)   Columbia agrees to indemnify and hold harmless
Serono and its Affiliates and their respective employees, agents, officers and
directors from and against any claims, losses, liabilities, damages, costs and
expenses (including reasonable attorneys' fees) incurred by Serono or its
Affiliates arising out of or in connection with any (A) breach by Columbia or
Columbia Bermuda of any representation, warranty, covenant or obligation
hereunder, (B) claim or demand of any kind for injury to person or property
arising from Columbia's or its sublicensees' marketing, Promotion, distribution
or sale of the Product, (C) negligent or intentional act or omission on the part
of Columbia, its sublicensees, Columbia Bermuda or any of their employees or
agents in the performance of this Agreement, or (D) payments, commissions or
fees of any kind due to consultants or brokers retained by Columbia relating to
the Product.

                          (iii)  A party seeking indemnification under this
Section 7 (the "Indemnified Party") must give prompt written notice thereof to
the other party (the "Indemnifying Party"). The Indemnifying Party shall have
the right to defend any such claim or demand subject to the right of the
Indemnified Party to participate with counsel of its choice in such defense,
but the fees and expenses of such additional counsel shall be at the expense
of the Indemnified Party. The Indemnified Party shall cooperate fully in all
respects with the Indemnifying Party in any such compromise, settlement or
defense, including, without limitation, by making available all pertinent
information and personnel under its control to the Indemnifying Party. The
Indemnifying Party will not compromise or settle any claim or demand (other
than, after consultation with the Indemnified Party, a claim or demand to be
settled by the payment of money damages and/or the granting of releases)
without the prior written consent of the Indemnified Party, which consent
shall not be unreasonably withheld.

         8.       Insurance. Columbia shall maintain and keep in force for the
term of this Agreement comprehensive general liability insurance including
Products/Completed Operations,

    [***] A CONFIDENTIAL PORTION OF THE MATERIAL HAS BEEN OMITTED AND FILED
             SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.

                                     - 10 -

<PAGE>

Contractual and Broad Form Property Damage covering its indemnification
obligations hereunder with a minimum limit of [***]United States Dollars (U.S.
$[***]) per annum combined single limit for Bodily Injury and Property Damage.
Such insurance shall be placed with a first class insurance carrier with at
least a BBB rating by Standard & Poor's, and shall name Ares as an additional
insured. Upon the execution and delivery of this Agreement, Columbia shall
furnish a certificate of insurance to Serono evidencing the foregoing
endorsements, coverage and limits, and providing that such insurance shall not
expire or be canceled or modified without at least thirty (30) days prior notice
to Serono.

         9.       Term of License. The term of this Agreement (the "Term")
shall commence on the Effective Date and continue until terminated in accordance
with the provisions of Section 10.

        10.       Termination.
                  -----------

                  (a)     This Agreement shall automatically terminate upon the
         expiration or termination of the License and Supply Agreement.

                  (b)     This Agreement may be terminated upon the mutual
         written agreement of the parties.

                  (c)     Serono may terminate this Agreement upon written
         notice to Columbia in the event that (i) the number of Units of
         Columbia's Product dispensed to patients within the Fertility
         Specialist Market in any calendar quarter, as determined under Section
         5(a)(iii), equals or exceeds [***]percent ([***]%) of the number of
         Units of Serono's Product dispensed to patients within the Fertility
         Specialist Market in such calendar quarter, as determined under Section
         5(a)(iii), (ii) Serono notifies Columbia in writing of Serono's intent
         to terminate this Agreement under this Section 10(c), and (iii) the
         number of Units of Columbia's Product dispensed to patients within the
         Fertility Specialist Market equals or exceeds [***]percent ([***]%) of
         the number of Units of Serono's Product dispensed to patients within
         the Fertility Specialist Market during the three full calendar month
         period immediately following receipt of such notice (the "Cure
         Period"); provided, however, that Serono may immediately terminate this
         Agreement at any time after the Cure Period upon written notice to
         Columbia in the event that the number of Units of Columbia's Product
         dispensed to patients within the Fertility Specialist Market in any
         three-month period after the Cure Period (and not including any month
         during the Cure Period) equals or exceeds [***]percent ([***]%) of the
         number of Units of Serono's Product dispensed to patients within the
         Fertility Specialist Market in such three-month period.

                  (d)     Serono or Columbia may terminate this Agreement
         forthwith by written notice to the other, if the other party commits a
         material breach of any part of this Agreement and such breach has not
         been remedied by the breaching party within sixty (60) days after
         written notice of such breach has been given by the other party.

                  (e)     Serono may terminate this Agreement at any time that
         Ares is entitled to terminate the License and Supply Agreement pursuant
         to Section 14(b) of the License and Supply Agreement due to a material
         breach by Columbia Bermuda which is not

    [***] A CONFIDENTIAL PORTION OF THE MATERIAL HAS BEEN OMITTED AND FILED
             SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.

                                     - 11 -

<PAGE>

         remedied within the sixty (60) day cure period of the License and
         Supply Agreement or such longer period made part of any applicable cure
         plan.

                  (f)     This Agreement may also be terminated by written
         notice of Serono, if Columbia becomes involved in financial
         difficulties as evidenced:

                          (i)    by its commencement of a voluntary case under
any applicable bankruptcy code or statute, or by its authorizing, by appropriate
proceedings, the commencement of such voluntary case; or

                          (ii)   by its failing to receive dismissal of any
involuntary case under any applicable bankruptcy code or statute within sixty
(60) days after initiation of such action or petition; or

                          (iii)  by its seeking relief as a debtor under any
applicable law of any jurisdiction relating to the liquidation or reorganization
of debtors or to the modification or alteration of the rights of creditors, or
by consenting to or acquiescing in such relief, or

                          (iv)   by the entry of an order by a court of
competent jurisdiction finding it to be bankrupt or insolvent, or ordering or
approving its liquidation, reorganization or any modification or alteration of
the rights of its creditors or assuming custody of, or appointing a receiver or
other custodian for, all or a substantial part of its property or assets; or

                          (v)    by its making an assignment for the benefit of,
or entering into a composition with its creditors, or appointing or consenting
to the appointment of a receiver or other custodian for all or a substantial
part of its property.

                  (g)     The failure by a party to exercise its rights to
         terminate this Agreement pursuant to this Section 10 in the event of
         any occurrence giving rise thereto shall not constitute a waiver of
         such rights in the event of any subsequent occurrence.

                  (h)     Termination of this Agreement shall not release any
         party from its obligations accrued prior to the effective date of
         termination nor deprive any party from any rights that this Agreement
         provides shall survive termination. The obligations of the parties
         under Sections 5(a)(iv), 5(b), 6, 7(c), 10(h) and 12 through 26 shall
         remain in full force and effect and shall survive the termination of
         this Agreement.

         11.      Publicity.
                  ---------

         The parties hereto shall coordinate the preparation and issuance of any
public announcement of this Agreement. Any such announcement shall comply with
relevant Securities and Exchange Commission requirements and shall take into
account any reasonable concern regarding the trade. Columbia and Serono shall
approve in writing the wording of such announcement before release, such
approval not to be unreasonably withheld.

         12.      Audits.
                  ------

    [***] A CONFIDENTIAL PORTION OF THE MATERIAL HAS BEEN OMITTED AND FILED
             SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.

                                     - 12 -

<PAGE>

         Columbia shall keep accurate records of all Product sales and other
relevant data concerning the Product for a period of two (2) years following the
year in which such records were created. Once a year, upon reasonable notice, at
times mutually agreed upon and during business hours, each of Serono and AHPC,
at Serono's or AHPC's cost, as applicable, may have the accounts of Columbia and
its sublicensees for the preceding two (2) calendar years relating to the
Product reviewed by independent certified public accountants appointed by Serono
or AHPC, as applicable, and reasonably approved by Columbia, solely in order to
verify amounts due under this Agreement. Serono or AHPC, as applicable, and
Columbia shall mutually determine a general strategy for such audit in advance
of its conduct. Said accountant shall not disclose to Serono or AHPC any
information except that which should properly be contained in a quarterly report
required under this Agreement. Columbia shall promptly pay any underpayment
evidenced by such audit, and Serono shall promptly refund any overpayment
evidenced by such audit. In the event such an audit evidences an underpayment of
more than five percent (5%) with respect to the amounts actually paid, Columbia
shall promptly pay such underpayment to Serono with interest at the prime rate
as set by Citibank, from the time when such underpayment accrued, and shall
reimburse Serono for the reasonable costs and expenses (including fees) of such
audit.

         13.      Notices.
                  -------

         All notices required hereunder shall be in writing and shall be deemed
to be properly given if sent by air courier to the party to be notified at the
address set forth on page 1 hereof, or at such other latest address as a party
may hereafter designate in writing to the other; provided that a copy of each
notice to be sent to Columbia or Columbia Bermuda hereunder shall also be sent
by the same means to General Counsel, Columbia Laboratories, Inc. 220 South
Orange Avenue, Livingston, NJ 07039, USA, and further provided that a copy of
each notice sent to Ares or Serono hereunder shall also be sent by the same
means to General Counsel, Serono International S.A., 15 bis chemin des Mines,
1202, Geneva, Switzerland. The date of service of any notice so sent by air
courier shall be the date of receipt.

         14.      Ownership Change; Assignment; Successors.
                  ----------------------------------------

         This Agreement shall be binding on and inure to the benefit of the
successors and permitted assigns of the parties. No party may transfer or assign
this Agreement, in whole or in part, without the consent in writing of the other
parties, and any purported assignment without such consent (which may be
withheld without reason) shall be void; provided, that a party may upon notice
to the other parties assign all or any portion of this Agreement to any of its
Affiliates or to an assignee of the License and Supply Agreement in connection
with a permitted assignment under the License and Supply Agreement. No party
may, following such an assignment to an Affiliate, sell such Affiliate without
the other party's prior written consent unless this Agreement is first assigned
back from such Affiliate to the assigning party. Nothing in this Agreement,
express or implied, is intended to confer on any person other than the parties
hereto, or their respective permitted successors and assigns, any benefits,
rights or remedies.

         15.      Tax.
                  ---

    [***] A CONFIDENTIAL PORTION OF THE MATERIAL HAS BEEN OMITTED AND FILED
             SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.

                                     - 13 -

<PAGE>

         All taxes levied on account of any payments accruing under this
Agreement which constitute income to Serono, shall be the obligation of Serono,
and if provision is made in law or regulation for withholding, such tax shall be
deducted from any payment then due, paid to the proper taxing authority, and
receipt for payment of the tax secured and promptly sent to Serono.

         16.      Independent Contractors.
                  -----------------------

         The relationship of the parties under this Agreement is that of
independent contractors. Neither party shall be deemed to be the agent, partner
or joint venturer of the other and neither is authorized to take any action
binding upon the other.

         17.      Entire Agreement; Modification.
                  ------------------------------

         This Agreement, including the Exhibits hereto, contains the entire
understanding between the parties hereto relating to the subject matter hereof,
there being no terms and conditions other than those set forth herein, and it
supersedes all prior agreements, statements or representations, written or oral,
between the parties hereto with respect to the matters covered hereunder. This
Agreement may not be modified, altered or otherwise changed or any of its
provisions waived other than by an instrument in writing, duly executed by each
of the parties hereto. In the event of a conflict between the terms of this
Agreement and the terms of the License and Supply Agreement, the terms of the
License and Supply Agreement shall control.

         18.      Severability.
                  ------------

         If any provision of this Agreement should be or becomes fully or partly
invalid or unenforceable for any reason whatsoever or should be adjudged to
violate any applicable law, this Agreement is to be considered divisible as to
such provision and such provision is deemed to be deleted from this Agreement,
and the remainder of this Agreement shall be valid and binding as if such
provision were not included herein; provided, however, that this Agreement is
not rendered fundamentally different in its content or effect.

         19.      Effect of Headings.
                  ------------------

         The headings for the sections and paragraphs of this Agreement are to
facilitate reference only, do not form a party of this Agreement, and shall not
in any way affect the interpretation hereof.

         20.      Choice of Law.
                  -------------

         This Agreement and performance hereof shall be construed and governed
by the laws of the State of New York without regard to its rules on conflict of
laws. Any dispute, controversy, claim or difference arising between the parties
out of, relating to, or in connection with this Agreement shall be submitted to
the jurisdiction of the courts sitting in the State of New York.

         21.      No Waiver.
                  ---------

    [***] A CONFIDENTIAL PORTION OF THE MATERIAL HAS BEEN OMITTED AND FILED
             SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.

                                     - 14 -

<PAGE>

         No delay or omission or failure to exercise any right or remedy
provided for herein shall be deemed to be a waiver thereof or acquiescence to
the event giving rise to such right or remedy.

         22.      Counterparts.
                  ------------

         This Agreement may be executed in any number of counterparts and by the
parties hereto on separate counterparts, each of which, when so executed shall
be deemed an original, but all such counterparts shall constitute but one and
the same instrument.

         23.      Further Assurances.
                  ------------------

         The parties each agree to produce or execute such other documents or
agreements as may be necessary or desirable for the execution and implementation
of this Agreement and the consummation of the transactions contemplated hereby.

         24.      Exhibits.
                  --------

         The terms and provisions of the Exhibits attached to this Agreement are
hereby incorporated herein as if fully set forth herein.

         25.      Bankruptcy.
                  ----------

         All Patent and Technology rights and licenses granted to the Product
under or pursuant to this Agreement by Serono to Columbia are, and shall
otherwise be deemed to be, for purposes of Section 365(n) of the United States
Bankruptcy Code, as amended from time to time (the "Bankruptcy Code"), licenses
of rights to "intellectual property" as defined under Section 101 (35A) of the
Bankruptcy Code. The parties hereto agree that so long as Columbia, as a
licensee of such rights under this Agreement, makes all payments to Serono
required under this Agreement, Columbia shall retain and may fully exercise all
of its rights and elections under the Bankruptcy Code. The parties further agree
that, in the event that any proceeding shall be instituted by or against Ares or
Serono seeking to adjudicate it as bankrupt or insolvent, or seeking
liquidation, winding up, reorganization, arrangement, adjustment, protection,
relief or composition of it or its debts under any law relating to bankruptcy,
insolvency or reorganization or relief of debtors, or seeking an entry of an
order for relief or the appointment of a receiver, trustee or other similar
official for it or any substantial part of its property or it shall take an
action to authorize any of the foregoing actions, Columbia, as a licensee of
such rights under this Agreement, shall retain and may fully exercise all of its
rights and elections under the Bankruptcy Code.

         26.      Performance by Affiliates.
                  -------------------------

         The parties acknowledge that certain of their rights and obligations
under this Agreement may be carried out by one or more of their Affiliates;
provided, however, that each party shall remain responsible for the acts and
omission of its Affiliates. The parties further understand and agree that no
such Affiliate is a party to this Agreement, and, except as contemplated by this
Agreement, is not the agent of such party for purposes hereof, is not authorized
to bind such

    [***] A CONFIDENTIAL PORTION OF THE MATERIAL HAS BEEN OMITTED AND FILED
             SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.

                                     - 15 -

<PAGE>

party and cannot enter into amendments to this Agreement, which can only be made
in accordance with the terms of Section 17 hereof.

    [***] A CONFIDENTIAL PORTION OF THE MATERIAL HAS BEEN OMITTED AND FILED
             SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.

                                     - 16 -

<PAGE>

         IN WITNESS WHEREOF, the parties have caused this Agreement to be
executed under seal as of the date first written above by their duly authorized
representatives.

                                        COLUMBIA LABORATORIES (BERMUDA) LIMITED

                                        By: /S/ William J. Bologna
                                            ----------------------
                                            Name: William J. Bologna
                                            Title: Director

                                        COLUMBIA LABORATORIES, INC.

                                        By: /S/ Fred Wilkinson
                                            ------------------
                                            Name: Fred Wilkinson
                                            Title: President & CEO

                                        ARES TRADING S.A.

                                        By: /S/ Jean - Pierre Verhassel
                                            ---------------------------
                                            Name: Jean - Pierre Verhassel
                                            Title: Authorized Representative

                                        By: /S/ Jacques Theurillat
                                            ----------------------
                                            Name: Jacques Theurillat
                                            Title: Authorized Representative

                                        SERONO, INC.

                                        By: /S/ Jean - Pierre Verhassel
                                            ---------------------------
                                            Name: Jean - Pierre Verhassel
                                            Title: Authorized Representative

    [***] A CONFIDENTIAL PORTION OF THE MATERIAL HAS BEEN OMITTED AND FILED
             SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.

                                     - 17 -

<PAGE>

                                                                  DRAFT 5/14/02

                                    EXHIBIT A
                                Ares' Trade Dress

                                [LOGO] Crinone

    [***] A CONFIDENTIAL PORTION OF THE MATERIAL HAS BEEN OMITTED AND FILED
             SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.

<PAGE>

                                    EXHIBIT B
                                 Form of Report
                           Quarterly Period: _________

I.       DISPENSING DATA SOURCES:

Prescriber Data:
         [[***]]
         [[***]]

Non-Retail Data:
         [[***]]

II.      DISPENSING DATA:

<TABLE>
<CAPTION>
---------------------------------------------------------------------------------------------------------------------
    Data Label      Data Description and Determination Methodology                                   Data Value
---------------------------------------------------------------------------------------------------------------------
        <S>         <C>
        A           No. of Units of Columbia's Product dispensed to patients within the Fertility
                    Specialist Market as shown by Prescriber Data
---------------------------------------------------------------------------------------------------------------------
        B           No. of Units of Columbia's Product dispensed to patients within the
                    Non-Fertility Specialist Market as shown by Prescriber Data
---------------------------------------------------------------------------------------------------------------------
        C           No. of Units of Columbia's Product sold by wholesalers to non-retail
                    prescribing organizations as shown by Non-Retail Data
---------------------------------------------------------------------------------------------------------------------
                    No. of Units of Columbia's Product dispensed to patients within the Fertility
                    Specialist Market
        D           determined by using the following formula:
                    A + ((A/(A+B)) x C)/1/
---------------------------------------------------------------------------------------------------------------------
                    [***]% of Columbia's wholesale acquisition cost (WAC) for Columbia's Product
        E           on a per-package basis in effect at the end of the applicable quarter / No. of
                    Units per package*
---------------------------------------------------------------------------------------------------------------------
                    Columbia's Net Sales of Product dispensed to patients within the Fertility
                    Specialist Market
        F           determined by using the following formula:
                    D x E
---------------------------------------------------------------------------------------------------------------------
        G           No. of Units of Serono's Product dispensed to patients within the Fertility
                    Specialist Market as shown by Prescriber Data
---------------------------------------------------------------------------------------------------------------------
        H           No. of Units of Serono's Product dispensed to patients within the
                    Non-Fertility Specialist Market as shown by Prescriber Data
---------------------------------------------------------------------------------------------------------------------
        I           No. of Units of Serono's Product sold by wholesalers to non-retail prescribing
                    organizations as shown by Non-Retail Data
---------------------------------------------------------------------------------------------------------------------
        J           No. of Units of Serono's Product dispensed to patients within the
---------------------------------------------------------------------------------------------------------------------
</TABLE>

-----------------------
/1/ In any quarter in which Serono has not offered Product A for sale at all
    times during such quarter and Columbia has offered Product A for sale at all
    times during such quarter, the no. of Units of Columbia's Product dispensed
    to patients within the Fertility Specialist Market during such quarter shall
    be reduced by the lesser of (i) [***]Units or (ii) the no. of Units of
    Product A dispensed by Columbia to patients within the Fertility Specialist
    Market during such quarter. This reduction shall be solely for the purposes
    of determining Serono's termination right under Section 10(c).

    [***] A CONFIDENTIAL PORTION OF THE MATERIAL HAS BEEN OMITTED AND FILED
             SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.

                                     - 19 -

<PAGE>

<TABLE>
---------------------------------------------------------------------------------------------------------------------
        <S>         <C>
                    Fertility Specialist Market
                    determined by using the following formula:
                    G + ((G/(G+H)) x I)
---------------------------------------------------------------------------------------------------------------------
                    No. of Units of Serono's Product dispensed to patients within the
        K           Non-Fertility Specialist Market determined by using the following formula:  H
                    + ((H/G+H) x I)
---------------------------------------------------------------------------------------------------------------------
                    [***]% of Serono's wholesale acquisition cost (WAC) for Serono's Product on a
        L           per-package basis in effect at the end of the applicable quarter / No. of
                    Units per package*
---------------------------------------------------------------------------------------------------------------------
        M           Ares' Net Sales of Product through Serono dispensed to
                    patients within the Non-Fertility Specialist Market
                    determined by using the following formula:
                    K x L
---------------------------------------------------------------------------------------------------------------------
</TABLE>

III.     PAYMENT AMOUNTS:

Columbia to Serono (pursuant to Section 5 of the Marketing License Agreement):

         Payment Amount = F x 40%

Serono to Columbia (pursuant to Section 5 of the Amended and Restated License
and Supply Agreement):

         Payment Amount = M x 40%

IV.      NOTES:

*If Product A and Product B have different per-Unit WACs, then this report will
include additional calculations reflecting such difference.

    [***] A CONFIDENTIAL PORTION OF THE MATERIAL HAS BEEN OMITTED AND FILED
             SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.

                                     - 20 -<PAGE>

Exhibit 10.34

                            MASTER SERVICES AGREEMENT

This Master Services Agreement (this "Master Agreement"), with an Effective Date
of July 31, 2002, will set forth the terms and conditions between Columbia
Laboratories, Inc., 220 South Orange Avenue, Livingston, NJ 07039 (hereinafter
"Columbia"), and Innovex LP, 10 Waterview Boulevard, Parsippany, NJ 07054
(hereinafter "Innovex").

                                   BACKGROUND:

         A.       Columbia is in the business of developing, manufacturing,
and distributing pharmaceutical products for women's health care, including
Prochieve(TM) 4% Progesterone Gel, Prochieve(TM) 8% Progesterone Gel,
Advantage-S(R) Bioadhesive Contraceptive Gel, and RepHresh Vaginal Gel(TM)
("Columbia Product(s)"). Innovex is in the business of providing sales,
marketing and alternative commercialization services for the pharmaceutical,
healthcare and biotechnology industries.

         B.       Columbia and Innovex desire to enter into this Master
Agreement to provide the terms and conditions upon which Columbia may engage
Innovex and its corporate Affiliates from time-to-time to provide contract sales
services for the Columbia Products by executing individual Work Orders (as
defined below) specifying the details of the services and the related terms and
conditions.

                                   AGREEMENT:

1.0      DEFINITIONS

         1.1      "Affiliate" shall mean any corporation or business entity
                  controlled by, controlling, or under common control with a
                  party to this Agreement. For this purpose, "control" shall
                  mean direct or indirect beneficial ownership of at least fifty
                  percent (50%) of the voting stock or income interest in such
                  corporation or other business entity, or such other
                  relationship as, in fact, constitutes actual control.

        1.2       "Bioadhesive Delivery System" shall mean Columbia's
                  proprietary and patented drug delivery systems.

        1.3       "FDA" shall mean the US Food and Drug Administration.

        1.4       "Fees" shall mean the compensation payable to Innovex by
                  Columbia in return for Services. Fees shall not include
                  Pass-Through Expenses.

        1.5       "Pass-Through Expenses" shall mean the reasonable and
                  necessary out-of-pocket costs and expenses actually incurred
                  by Innovex in providing Services, in accordance with the
                  express terms of a Work Order.

    [***] A CONFIDENTIAL PORTION OF THE MATERIAL HAS BEEN OMITTED AND FILED
            SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.

                                       1

<PAGE>

        1.6       "Project" shall mean the complete task or set of tasks
                  described in a specific Work Order.

        1.7       "Services" shall mean the responsibilities, obligations and
                  activities which are to be performed by Innovex, as they are
                  described in this Agreement and in specific Work Orders.

        1.8       "Term" and "Project Term" shall have the meanings described in
                  Section 11.1.

        1.9       "Work Order" shall have the meaning described in Section 2.2.

2.      SCOPE OF THE AGREEMENT; SERVICES TO BE PROVIDED; WORK ORDERS; PROJECT
        TEAMS.

2.1     Scope of Agreement. This Master Agreement allows the parties to contract
        for multiple Projects through the issuance of multiple Work Orders. This
        Master Agreement covers the provision of professional sales and
        marketing services by Innovex and Innovex's corporate Affiliates (see
        Section 11), including, but not limited to, recruitment and hiring of
        sales personnel, full-time or flex-time sales force services,
        promotional education programs and other related commercialization
        services, when requested by Columbia and agreed to by Innovex as set
        forth in the relevant Work Order. Columbia shall, in its sole
        discretion, determine when and whether to offer projects to Innovex and
        its corporate Affiliates, including the decision whether or not to enter
        into a specific Work Order.

2.2     Work Orders. The specific details and tasks of each Project shall be
        separately negotiated and specified in writing on terms and in a form
        acceptable to the parties (each such writing, a "Work Order"). The first
        Work Order is of even date hereof and subsequently issued Work Orders
        may follow, or differ materially from, the same basic template. Each
        Work Order may include, as appropriate, identification of the Columbia
        Products to be involved in the Services, a schedule of Innovex
        Responsibilities and Obligations, Columbia Responsibilities and
        Obligations and Fees and Pass-Through Expenses. Each Work Order shall be
        subject to all of the terms and conditions of this Master Agreement, in
        addition to the specific details set forth in the Work Order. To the
        extent any terms or provisions of a Work Order conflict with the terms
        and provisions of this Master Agreement, the terms and provisions of
        this Master Agreement shall control, unless the Work Order expressly and
        specifically states an intent to supersede the Master Agreement on a
        specific matter (but then only with respect to the particular Work Order
        and with respect only to the matter so specified). A change in a Work
        Order shall be evidenced by an amendment to the relevant Work Order duly
        executed by Columbia and Innovex in form acceptable to both parties.

3.      PAYMENT OF FEES AND PASS-THROUGH EXPENSES.

3.1     Columbia shall pay Innovex the Fees and Pass-Through Expenses expressly
        described in each Work Order. Unless otherwise agreed in a particular
        Work Order, Innovex will invoice Columbia monthly for the Fees and
        Pass-Through Expenses relating to the Project. Each

    [***] A CONFIDENTIAL PORTION OF THE MATERIAL HAS BEEN OMITTED AND FILED
            SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.

                                       2

<PAGE>

        invoice shall be supported by a detailed expense report, and supporting
        documentation. Notwithstanding the foregoing, Innovex will use its best
        efforts to audit expense reports submitted by its Sales Force (prior to
        submitting monthly expenses to Columbia) to ensure the expenses detailed
        in such expense reports were appropriately incurred in support of the
        Services to Columbia. Columbia shall make payment within 30 days after
        the receipt of each monthly itemized invoice. If any portion of an
        invoice is disputed, Columbia shall pay the undisputed amounts within
        the aforementioned 30 days, and the parties shall use good faith efforts
        to reconcile the disputed amount for payment as soon as practicable.

3.2     If the period of non-payment of an undisputed amount exceeds 45 days
        from the date of receipt of the invoice, Innovex may, at its sole
        discretion and without prejudice to any other rights or remedies, give
        Columbia a ten (10) day written notice of intent to suspend Services in
        connection with the Project, and if the non-payment continues after the
        ten (10) day period, Innovex may (i) suspend the Services on that
        Project or (ii) exercise its right to give notice of a default in
        accordance with Section 11.3.

3.3     Payments shall be by wire-transfer or by check as follows:

                  Innovex LP
                  Accounting Number:                 511-4454518
                  ABA Number:                        053 101 121
                  Branch Banking & Trust Co., Raleigh, NC

        Innovex Federal Employment ID Number is 22-3760578.

4.      CONFIDENTIALITY AND OWNERSHIP OF INFORMATION.

4.1     Each of the parties acknowledges that, in the course of performing its
        obligations hereunder, it may receive information from the other party
        which is proprietary to the disclosing party and which the disclosing
        party wishes to protect from public disclosure ("Confidential
        Information"). Innovex and Columbia agree to retain in confidence,
        during the Term of this Agreement and any Work Order, and any subsequent
        renewals thereof, and thereafter for a period of seven (7) years, all
        Confidential Information disclosed to it by or on behalf of the other
        party, and that it will not, without the written consent of such other
        party, use Confidential Information for any purpose other than the
        purposes indicated herein. These restrictions shall not apply to
        Confidential Information which: (i) is or becomes public knowledge
        (through no fault of the receiving party); (ii) is made lawfully
        available to the receiving party by an independent third party; (iii) is
        already in the receiving party's possession at the time of receipt from
        the disclosing party (and such prior possession can be properly
        demonstrated by the receiving party); (iv) is independently developed by
        the receiving party and/or Affiliates (and such independent development
        can be properly demonstrated by the receiving party); or (v) is required
        by law, regulation, rule, act or order of any governmental authority or
        agency to be disclosed by the receiving party, provided, however, if
        reasonably possible, such receiving party gives the disclosing party
        sufficient advance written notice to permit it to seek a protective
        order or other similar order with

    [***] A CONFIDENTIAL PORTION OF THE MATERIAL HAS BEEN OMITTED AND FILED
            SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.

                                       3

<PAGE>

        respect to such Confidential Information and, thereafter, the receiving
        party discloses only the minimum Confidential Information required to be
        disclosed in order to comply.

4.2     Innovex and Columbia shall limit disclosure of the other party's
        Confidential Information to only those of their respective officers,
        representatives, agents and employees (collectively "Agents") who are
        directly concerned with the performance of this Agreement and have a
        legitimate need to know such Confidential Information. Upon receipt of a
        request from either party, each party shall return all Confidential
        Information of the other within thirty (30) days of such request;
        provided, however, that each party can maintain one copy of the other's
        confidential information to monitor compliance with the confidentiality
        terms of this Master Agreement, to satisfy regulatory requirements or to
        resolve disputes regarding the Services.

4.3     All Columbia patents, trade secrets, copyrights, trade names,
        trademarks, service marks, proprietary materials or intellectual
        property and all improvements to any of the foregoing (collectively
        "Columbia Property") used in connection with the Services provided
        pursuant to this Master Agreement or any Work Order shall remain the
        sole and exclusive property of Columbia, and Innovex's rights to use
        such Columbia Property shall be limited to those permitted by this
        Master Agreement or any Work Order. Columbia and Innovex agree that any
        Columbia Property or improvements thereto which are used, improved,
        modified or developed by Columbia under or during the term of this
        Master Agreement or any Work Order are the sole and exclusive property
        of Columbia.

4.4     Columbia acknowledges that Innovex possesses certain inventions,
        processes, know-how, trade secrets, improvements, other intellectual
        properties and other assets, including but not limited to analytical
        methods, procedures and techniques, computer technical expertise and
        software, and business practices, including, but not limited to the
        Innovex Territory Management System (ITMS), the Innovex Build-A-Call(R)
        Pharmaceutical Selling Skills System, and the Innovex Sample
        Accountability System, which have been independently developed by
        Innovex (collectively "Innovex Property"). Columbia and Innovex agree
        that any Innovex Property or improvements thereto which are used,
        improved, modified or developed by Innovex under or during the term of
        this Master Agreement or any Work Order are the sole and exclusive
        property of Innovex.

4.5     No public announcement or other disclosure to any third party concerning
        the existence, or terms, of this Master Agreement, the Investment and
        Royalty Agreement, the Stock Purchase Agreement, the Work Order, and any
        other document or agreement executed in connection with this transaction
        (the "Transaction Documents") shall be made, either directly or
        indirectly, by any party hereto, except as may be legally required or as
        may be required for financial reporting purposes, without first
        obtaining the written approval of the other party and agreement upon the
        nature and text of such announcement or disclosure. Each party agrees
        that it shall cooperate fully with the other with respect to all
        disclosures regarding the Transaction Documents to the Securities
        Exchange Commission and any other governmental or regulatory agencies or
        any third party, including requests for confidential treatment of
        proprietary information of any party included in any such disclosure.

    [***] A CONFIDENTIAL PORTION OF THE MATERIAL HAS BEEN OMITTED AND FILED
            SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.

                                       4

<PAGE>

4.6     Columbia shall have and retain sole and exclusive right, title and
        interest in and to all inventions, discoveries, formulae, writings,
        trade secrets, know-how, methods, practices, procedures, processes,
        techniques, engineering information, marks, designs, devices,
        improvements, manufacturing information and other technology, whether or
        not patentable, trademarkable or copyrightable, and any patent
        applications, patents, trademarks or copyrights based thereon
        ("Inventions"), whether or not patentable, that are made, discovered,
        conceived, reduced to practice or generated by Columbia (or its
        employees or representatives) or by Innovex's employees or Agents that
        in any way relate to the Columbia Products or the Bioadhesive Delivery
        System or to the marketing or sales of Columbia Products in particular
        (as opposed to relating to the marketing or sales of pharmaceutical
        products generally). Innovex's employees or Agents will promptly
        disclose to Columbia, or any person designated by it, all Inventions. At
        Columbia's expense, Innovex's employees or Agents will assist Columbia
        in every reasonable manner to obtain and, from time to time, to enforce
        patents on said Inventions in any and all countries and will execute all
        documents Columbia may desire for such purpose, together with any
        assignments of such patents to Columbia or persons designated by it.

4.7     Innovex's employees or Agents hereby irrevocably transfer and assign to
        Columbia full ownership of the copyrights in the work created pursuant
        to this agreement ("Work"). Columbia shall have all rights, title, and
        interest in and to the Work, including the sole and exclusive right to
        secure and own the copyright registrations and renewals throughout the
        world. Accordingly, this agreement will constitute an assignment of
        copyrights in the Work and Innovex's employees or Agents agreement to
        cooperate with Columbia and execute any and all other documents
        appropriate to evidence sole proprietary rights and copyrights in the
        Work to Columbia. On termination of this Agreement for any reason,
        Innovex will transfer, assign, and make available to Columbia all text
        and other materials, regardless of their stage of development, that
        Innovex's employees or Agents have created or prepared on behalf of
        Columbia.

5.      INDEPENDENT CONTRACTOR RELATIONSHIP.

5.1     For the purposes of this Master Agreement and any Work Order, the
        parties hereto are independent contractors and nothing contained in this
        Master Agreement or any Work Order shall be construed to place them in
        the relationship of partners, principal and agent, employer and employee
        or joint venturers. Neither party shall have the power or right to bind
        or obligate the other party, nor shall either party hold itself out as
        having such authority.

5.2     No provision of this Master Agreement or any Work Order shall be deemed
        to create or imply any contract of employment between Columbia and any
        employee of Innovex. All persons performing Services shall be employees
        of Innovex, or subcontractors engaged by Innovex with prior consent of
        Columbia, and shall not be entitled to any benefits applicable to
        employees of Columbia.

5.3     Innovex will, among other things, (i) maintain all necessary personnel
        and payroll records for Innovex employees; (ii) compute wages and
        withhold applicable Federal, State and local

    [***] A CONFIDENTIAL PORTION OF THE MATERIAL HAS BEEN OMITTED AND FILED
            SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.

                                       5

<PAGE>

        taxes and Federal FICA payments for Innovex employees; (iii) remit
        Innovex employee withholdings to the proper governmental authorities
        and make employer contributions for Federal FICA and Federal and State
        unemployment insurance payments; (iv) pay net wages and fringe benefits,
        if any, directly to Innovex employees; and (v) provide for employer's
        liability and Workers' Compensation insurance coverage.

5.4     Innovex shall be responsible for management of all employer obligations
        in connection with Innovex employees who perform the Services. Innovex
        employees shall remain exclusively under the direct authority and
        control of Innovex. Columbia may be involved in providing training,
        direction or equipment to an Innovex employee only in the manner and to
        the extent specifically described in a Work Order. The employer
        obligations of Innovex shall include, without limitation: (i) human
        resource issues, including establishment of employee policies, and
        administration of health and benefits plans, 401K plan, and other
        employee benefit plans; (ii) work performance and work behavior issues,
        including probationary period, periodic and annual appraisals, employee
        discipline and termination; (iii) administration of systems for
        time-keeping, payroll and employee expense reimbursement; and (iv) day
        to day management of employment issues in connection with performance of
        the Services.

5.5     Innovex agrees that it controls the work site and the scheduling of its
        employees. Innovex will not violate any applicable law pertaining to the
        payments of wages to its employees. Innovex is responsible for and
        hereby agrees to comply with the following: (i) all rules and
        regulations governing the reporting, collection and payment of federal
        and state payroll taxes on wages paid to Innovex's employees, including,
        but not limited to (a) federal income tax withholding provisions of the
        Internal Revenue Code; (b) state and/or local income tax withholding
        provisions, if applicable; (c) Federal Insurance Contribution Act
        (FICA); (d) Federal Unemployment Tax Act (FUTA) and (e) applicable state
        unemployment tax provisions (SUTA); (ii) applicable workers'
        compensation laws including, but not limited to: (a) procuring workers'
        compensation insurance; (b) completing and filing all required reports;
        and (c) administering, managing and otherwise processing claims and
        related procedures; (iii) Internal Revenue Code Section 4980B (COBRA);
        (iv) the Consumer Credit Protection Act, Title III; and (v) all rules
        and regulations governing administration, procurement and payment of all
        other employee benefits specified in a Work Order or covered by this
        Master Agreement.

6.      REGULATORY COMPLIANCE.

6.1     In carrying out their responsibilities under this Master Agreement and
        each Work Order, Innovex and Columbia agree to comply, to the extent
        applicable, with all laws, rules and regulations, including, but not
        limited to the Federal Equal Employment Opportunity Act, Title VII of
        the Civil Rights Act of 1964, the Age Discrimination in Employment Act,
        the Americans with Disabilities Act, the Fair Labor Standards Act, the
        Immigration Reform and Control Act of 1986, the Food, Drug and Cosmetic
        Act, Section 1128B(b) of the Social Security Act (42 U.S.C.
        [sec]1320a-7b(b)), and the Prescription Drug Marketing Act.

6.2     If Innovex or its employees become aware of adverse drug experience
        reports involving the use of any Columbia Product, while performing any
        Services in connection with the

    [***] A CONFIDENTIAL PORTION OF THE MATERIAL HAS BEEN OMITTED AND FILED
            SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.

                                       6

<PAGE>

        Columbia Product, they shall immediately notify Columbia in accordance
        with Columbia procedures in place from time to time. Columbia shall
        deliver to Innovex a written copy of such Columbia notification
        procedures.

6.3     Columbia shall be solely responsible for responding to any government or
        regulatory agency concerning use or marketing of Columbia Products,
        except where (i) such responsibility is expressly transferred to Innovex
        in a Work Order; or (ii) to the extent any notice or reporting
        requirement is by law made directly applicable to Innovex. Innovex shall
        promptly notify Columbia of any information Innovex receives regarding
        any threatened or pending action by a government or regulatory agency
        that may affect the Columbia Products. Innovex shall, at the request of
        Columbia, cooperate with Columbia in order to respond, or in formulating
        a procedure for taking appropriate action. In no event shall Innovex
        respond to any agency without the prior consent of Columbia, unless
        compelled to do so by law.

6.4     Innovex certifies that neither Innovex nor any Innovex employee or Agent
        has been debarred under Section 306(a) or (b) of the Federal Food, Drug
        and Cosmetic Act and no debarred person will in the future be employed
        by Innovex in connection with any work to be performed for or on behalf
        of Columbia. If at any time after execution of this Agreement, Innovex
        becomes aware that Innovex or an Innovex employee or Agent is, or is in
        the process of being, debarred, Innovex hereby certifies that it will so
        inform Columbia immediately.

7.      REPORTS AND PROJECT ADMINISTRATION

        Innovex will manage and administer each Project in accordance with the
        specifications and milestones contained in each Work Order. Innovex
        shall provide Columbia a periodic Project report, in the frequency and
        with content as more particularly described in each Work Order. The
        Project report shall generally include: (i) headcount, turnover, status
        of recruitment; (ii) Project status and progress toward achieving
        objectives or milestones; (iii) financial accountability, and tracking
        expenses against budget.

8.      RETURN OF COLUMBIA MATERIALS.

        Within thirty (30) days after the completion of Services by Innovex, or
        upon termination of the Master Agreement or any Work Order, Confidential
        Information, Columbia Property and other data owned by Columbia,
        regardless of the method of storage or retrieval, shall at Columbia's
        request either be delivered to Columbia in such form as is then
        currently in the possession of Innovex, or disposed of, at the direction
        and written request of Columbia, unless such materials are otherwise
        required to be stored or maintained by Innovex as a matter of law or
        regulation. Columbia shall pay the costs associated with any of the
        above options. Innovex reserves the right to retain, at its own expense
        and subject to the confidentiality provisions herein, one copy of all
        materials provided in connection with performance of the Services, to be
        used to satisfy regulatory requirements or to resolve disputes regarding
        the Services.

9.      INDEMNIFICATION AND LIABILITY LIMITS.

    [***] A CONFIDENTIAL PORTION OF THE MATERIAL HAS BEEN OMITTED AND FILED
            SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.

                                       7

<PAGE>

9.1     Innovex shall indemnify, defend and hold harmless Columbia, its
        Affiliates and its and their respective directors, officers, employees
        and agents from and against any and all losses, claims, actions,
        damages, liabilities, penalties, costs and expenses (including
        reasonable attorneys' fees and court costs) (collectively, "Losses"),
        resulting from any (i) breach by Innovex or its employees of its
        obligations hereunder; (ii) willful misconduct or negligent acts or
        omissions of Innovex or its employees; and (iii) violation by Innovex or
        its employees of any municipal, county, state or federal laws, rules or
        regulations applicable to the performance of Innovex's obligations under
        this Master Agreement or any Work Order, (iv) actions or incidents by
        Innovex of criminal or dishonest activity or such actions or incidents
        of its employees of which Innovex could have reasonably anticipated, (v)
        with respect to the Sales Force, those costs attendant to the
        administration of any collective bargaining agreement, and any
        liabilities or claims against Columbia arising out of Innovex's
        non-payment or payment to or participation in a labor organization's
        health and welfare retirement or other benefit fund, including the
        cessation of payment thereto or withdrawal from participation therein
        (unless such are caused by the actions or inactions of Columbia); (vi)
        violations by Innovex of employment-related matters with respect to
        Innovex's employees, including matters arising under local, state and/or
        federal right-to-know laws, environmental laws, NLRB, OSHA, EEOC, ADA
        (including without limitation those relating to employment, public
        access and public accommodation), WARN, FMLA, ERISA, all laws governing
        wages and hours (including without limitation: prevailing wage rate;
        exempt and non exempt status; child labor; and minimum wage and overtime
        matters), all laws governing race, sex, sexual harassment, retaliation,
        religion, veteran status, national origin, color, age, disability, and
        marital status, disclosed and undisclosed benefit plans, all other labor
        laws; in each case except to the extent such Losses are determined to
        have resulted from the negligence or willful misconduct of Columbia or
        its employees.

9.2     Columbia shall indemnify, defend and hold harmless Innovex, its
        Affiliates and its and their respective directors, officers, employees
        and agents from and against any and all Losses resulting from (i) the
        manufacture, storage, packaging, production, transportation,
        distribution, sale or other disposition of the Products by Columbia or
        its agents; (ii) breach by Columbia or its employees of its obligations
        hereunder; (iii) willful misconduct or negligent acts or omissions of
        Columbia or its employees; and (iv) violation by Columbia or its
        employees of any municipal, county, state or federal laws, rules or
        regulations applicable to the performance of Columbia's obligations
        under this Master Agreement or any Work Order; in each case except to
        the extent such Losses are determined to have resulted from the
        negligence or willful misconduct of Innovex or its employees.

9.3     The party seeking indemnification hereunder (the "Indemnified Party")
        shall: (a) give the party obligated to indemnify (the "Indemnifying
        Party") prompt written notice of any such claim or law suit (including a
        copy thereof); (b) cooperate fully with Indemnifying Party and its legal
        representatives in the investigation and defense of any matter the
        subject of indemnification; and (c) not unreasonably withhold its
        approval of the settlement of any such claim, liability, or action by
        Indemnifying Party covered by this Indemnification provision; provided,
        however, that Indemnified Party's failure to comply with its obligations
        pursuant to

    [***] A CONFIDENTIAL PORTION OF THE MATERIAL HAS BEEN OMITTED AND FILED
            SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.

                                       8

<PAGE>

        this Section 9.3 shall not constitute a breach of this Master Agreement
        nor relieve Indemnifying Party of its indemnification obligations
        pursuant to Section 9, except to the extent, if any, that Indemnifying
        Party's defense of the affected claim, action or proceeding actually was
        materially impaired thereby.

9.4     Neither party, nor its Affiliates, nor any of a party's or its
        Affiliate's directors, officers, employees, subcontractors or agents
        shall have any liability of any type to the other (including, but not
        limited to, contract, negligence and tort liability), for any loss of
        profits, opportunity or goodwill, or any type of special, incidental,
        indirect or consequential damage or loss, in connection with or arising
        out of this Master Agreement, any Work Order, or the Services performed
        by Innovex hereunder.

9.5     Innovex shall not be liable to Columbia for claims or losses arising out
        of the statements or representations of Innovex employees with respect
        to Columbia Products to the extent the statements or representations
        conform to the written or printed statements or representations made to
        Innovex and Innovex employees by Columbia with respect to the Columbia
        Products.

10.     INSURANCE.

10.1    Innovex shall, at its own cost and expense, obtain and maintain in full
        force and effect, the following insurance during the Term (and any
        subsequent renewals thereof): (i) worker's compensation insurance in
        accordance with the statutory requirements of each state in which the
        Services are to be performed; (ii) employer's liability insurance with a
        minimum limit of [***] dollars ($[***]); (iii) comprehensive general
        liability insurance, including contractual liability, with a minimum
        limit of [***]dollars ($[***]), combined single limit per occurrence;
        (iv) comprehensive auto liability, covering bodily injury and property
        damage, for owned, hired or non-owned automobiles with a minimum limit
        of [***]dollars ($[***]), combined single limit per occurrence; and (v)
        professional errors and omissions, with a minimum limit of [***]
        ($[***]), per occurrence.

10.2    Columbia shall, at its own cost and expense, obtain and maintain in full
        force and effect, the following insurance during the Term (and any
        subsequent renewals thereof): (i) worker's compensation insurance in
        accordance with the statutory requirements of each state in which it has
        employees; (ii) employer's liability insurance with a minimum limit of
        [***]dollars ($[***]); (iii) comprehensive general liability insurance,
        including contractual liability, with a minimum limit of [***]dollars
        ($[***]), combined single limit per occurrence; and (iv) products
        liability insurance covering the Products, with a minimum limit of [***]
        ($[***]).

10.3    Each party shall provide the other party an original signed certificate
        of insurance evidencing all coverage herein required, within thirty (30)
        days after the effective date of this Master Agreement. The certificate
        must provide that thirty (30) days prior written notice of cancellation
        or material change in insurance coverage will be provided. The insurance
        obligations hereunder may be met by a program of self-insurance.

    [***] A CONFIDENTIAL PORTION OF THE MATERIAL HAS BEEN OMITTED AND FILED
            SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.

                                       9

<PAGE>

11.     TERM AND TERMINATION.

11.1    This Master Agreement shall commence on the Effective Date and shall
        continue until terminated as hereinafter provided (the "Term"). Each
        Work Order shall include a statement of the Project start date and the
        Project end date (the "Project Term").

11.2    Columbia may terminate this Master Agreement without cause at any time
        during the Term of the Master Agreement on 120 days prior written notice
        to Innovex; provided however, notwithstanding such termination, the
        terms of this Master Agreement shall remain in full force and effect
        with regard to any existing Work Order until the expiration of such Work
        Order according to its terms. An individual Work Order under this Master
        Agreement may be terminated as set forth therein.

11.3    Either party may terminate this Master Agreement by written notice at
        any time if the other party defaults in the performance of its material
        obligations under the Master Agreement. Either party may terminate a
        Work Order by written notice at any time if the other party defaults in
        the performance of its material obligations under the Work Order. In the
        event of such default, the party declaring the default shall provide the
        defaulting party with written notice setting forth the nature of the
        default, and the defaulting party shall have thirty (30) days to cure
        the default. Provided, however, that if the nature of the default is
        such that it cannot reasonably be cured within thirty (30) days, the
        defaulting party may cure such default by commencing in good faith to
        cure such default promptly after its receipt of such written notice and
        prosecuting the cure of such default to completion with diligence and
        continuity within a reasonable time thereafter. If the defaulting party
        fails to cure the default within the foregoing time periods, the other
        party may terminate the Master Agreement or Work Order, as the case may
        be, by written notice to the defaulting party, which notice shall be
        effective upon receipt.

11.4    Either party may terminate this Agreement by written notice to the other
        party, effective upon receipt with no right to cure the default, if the
        other party files a petition for bankruptcy, reorganization or
        arrangement under any state statute, or makes an assignment for the
        benefit of creditors or takes advantage of any insolvency statute or
        similar statute, or if a receiver or trustee is appointed for the
        property and assets of the party and the receivership proceedings are
        not dismissed within sixty (60) days of such appointment.

11.5    In the event this Master Agreement or a Work Order is terminated,
        Columbia shall (a) pay to Innovex all Fees for Services rendered which
        are due and owing to Innovex because of any completed performance of
        Innovex's obligations prior to the effective date of termination; (b)
        pay all Pass-Through Expenses actually incurred by Innovex prior to the
        effective date of termination; and (c) pay any other costs which have
        been expressly identified in a Work Order as being due upon termination
        of such Work Order.

11.6    Termination of this Master Agreement or any Work Order for whatever
        reason shall not affect the accrued rights of either Innovex or Columbia
        arising under this Master Agreement or a Work Order, and all provisions
        which expressly or by implication survive the

    [***] A CONFIDENTIAL PORTION OF THE MATERIAL HAS BEEN OMITTED AND FILED
            SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.

                                      10

<PAGE>

        termination or expiration of the Master Agreement or a Work Order shall
        remain in full force and effect.

11.7    Either party may terminate this Master Agreement by written notice to
        the other party upon thirty (30) days written notice if no current,
        active Work Order is in place between the parties.

12.     RELATIONSHIP WITH AFFILIATES.

12.1    Columbia agrees that Innovex may utilize the Services of its corporate
        Affiliates to fulfill Innovex's obligations under this Master Agreement
        and any Work Order. Any Innovex Affiliate so utilized shall be (i)
        subject to all of the terms and conditions applicable to Innovex under
        this Master Agreement and the Work Order applicable to such Project(s),
        including, but not limited to, provisions establishing the standards for
        performance, and (ii) entitled to all rights and protections afforded
        Innovex under this Master Agreement and the Work Order applicable to
        such Project(s), including, but not limited to, the indemnity and
        limitation of liability protections set forth herein. Any such Affiliate
        of Innovex may execute a Work Order directly and, with respect to the
        corresponding Project, the rights and obligations of the parties shall
        be governed by all of the terms and conditions of this Master Agreement,
        to the same extent as if such Innovex Affiliate was a party to this
        Master Agreement.

12.2    Columbia and Innovex acknowledge that certain Affiliates of Columbia may
        utilize the services of Innovex (and its Affiliates) under this Master
        Agreement and under any Work Order. In such event, (i) Columbia shall
        cause such Columbia Affiliate to acknowledge and be bound by all the
        terms and conditions of this Master Agreement and the specific Work
        Order, and (ii) Columbia shall remain responsible and obligated under
        this Master Agreement and the Work Order, as if Columbia was directly
        receiving the Services provided to such Columbia Affiliate. Any such
        Affiliate of Columbia may execute a Work Order directly and, with
        respect to the corresponding Project, the rights and obligations of the
        parties shall be governed by all of the terms and conditions of this
        Master Agreement, to the same extent as if such Columbia Affiliate was a
        party to this Master Agreement.

13.     COOPERATION.

        All data and information in Columbia's possession or control necessary
        for Innovex to conduct Project assignments will be delivered by Columbia
        to Innovex. Innovex shall not be liable to Columbia nor be deemed to
        have breached this Master Agreement or any Work Order as a result of
        errors, delays or other consequences directly arising from Columbia's
        failure to provide documents, materials or information or to otherwise
        cooperate with Innovex in order for Innovex to timely and properly
        perform Innovex's obligations.

14.     FORCE MAJEURE.

        Neither party shall be liable to the other for delay or failure in the
        performance of the obligations on its part contained in this Agreement
        if and to the extent that such failure or

    [***] A CONFIDENTIAL PORTION OF THE MATERIAL HAS BEEN OMITTED AND FILED
            SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.

                                      11

<PAGE>

        delay is due to circumstances beyond its control which it could not have
        avoided by the exercise of reasonable diligence including but not
        limited to: act of God, war or insurrection; civil commotion;
        destruction of essential facilities or materials by earthquake, fire,
        flood or storm; act of government, labor disturbance (whether or not any
        such labor disturbance is within the power of the affected party to
        settle); epidemic; or other similar event; provided, however, that the
        party so affected shall notify the other party promptly should such
        circumstances arise, giving an indication of the likely extent and
        duration thereof, and shall use all commercially reasonable efforts to
        avoid, remove or alleviate such causes of non-performance and shall
        resume performance of its obligations hereunder with the utmost dispatch
        whenever such causes are removed. In the event of force majeure lasting
        more than three (3) months, the parties agree to meet and discuss how
        this Agreement can be justly and fairly implemented under the
        circumstances and if the parties are unable to agree upon how the
        Agreement can be implemented then either party may terminate the
        Agreement upon thirty (30) days written notice.

15.     REVIEW OF WORK; AUDIT.

        During the term of this Master Agreement and six (6) months thereafter,
        Innovex will permit Columbia's representative(s) (unless such
        representatives are competitors of Innovex), at reasonable times and in
        a reasonable manner, and at Columbia's expense, to (i) examine the work
        performed hereunder to determine that the Services are being conducted
        in accordance with the agreed terms, or (ii) audit the financial records
        related to Innovex's performance of the Services.

16.     NOTICES.

        Any notice required or permitted to be given by either party shall be in
        writing. All notices shall be to the parties and addresses listed below,
        and shall be sufficiently given (i) when received, if delivered
        personally or sent by facsimile transmission, or (ii) one business day
        after the date mailed or sent by an internationally recognized overnight
        delivery service.

        If to Innovex:           Innovex LP
                                 c/o President, Innovex America Holding Company
                                 10 Waterview Blvd.
                                 Parsippany, NJ 07054
                                 Attention:  President
                                 Fax: 973-257-4581

        With a copy to:          General Counsel
                                 Innovex America Holding Company
                                 10 Waterview Blvd
                                 Parsippany, NJ 07054
                                 Fax: 973-257-4581

        If to Columbia:          Columbia Laboratories, Inc.

    [***] A CONFIDENTIAL PORTION OF THE MATERIAL HAS BEEN OMITTED AND FILED
            SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.

                                      12

<PAGE>

                                 220 South Orange Avenue,
                                 Livingston, NJ 07039
                                 Attention:  President
                                 Fax: 973-994-3001

        With a copy to:          Columbia Laboratories, Inc.
                                 220 South Orange Avenue,
                                 Livingston, NJ 07039
                                 Attention:  General Counsel
                                 Fax: 973-994-3001

17.     ASSIGNMENT.

        Except for Affiliates, as stated above in Section 12, neither party may
        assign any of its rights or obligations under this Master Agreement or
        any Work Order to any third party without the written consent of the
        other party, which consent shall not be unreasonably withheld.

18.     ARBITRATION.

18.1    Resolution of disputes concerning any aspect of the Services, this
        Master Agreement or a Work Order, excluding termination, shall be
        accomplished by good faith negotiations between Columbia and Innovex,
        within thirty (30) days after notice. If necessary, thereafter,
        resolution of such disputes shall be accomplished, at written request of
        either party to the other party within 30 days following the end of such
        30 day period, by binding arbitration, which shall not interfere with
        the timely rendering of Services. The arbitration panel will be composed
        of three arbitrators, one of whom will be chosen by Columbia, one by
        Innovex, and the third by the two so chosen. If both or either of
        Columbia or Innovex fails to choose an arbitrator or arbitrators within
        fourteen (14) days after receiving notice of commencement of
        arbitration, or if the two arbitrators fail to choose a third arbitrator
        within fourteen (14) days after their appointment, the American
        Arbitration Association shall, upon the request of both or either of the
        parties to the arbitration, appoint the arbitrator or arbitrators
        required to complete the panel. The arbitrators shall have reasonable
        experience in the matter under dispute. The decision of the arbitrators
        shall be final and binding on the parties, and specific performance
        giving effect to the decision of the arbitrators may be ordered by any
        court of competent jurisdiction. Nothing contained herein shall operate
        to prevent either party from asserting counterclaim(s) in any
        arbitration commenced in accordance with this agreement.

18.2    The arbitration shall be filed with the office of the American
        Arbitration Association ("AAA") located in New York, New York or such
        other AAA office as the parties may agree upon (without any obligation
        to so agree). The arbitration shall be conducted pursuant to the
        Commercial Arbitration Rules of AAA as in effect at the time of the
        arbitration hearing, such arbitration to be completed in a sixty (60)
        day period. In addition, the following rules and procedures shall apply
        to the arbitration.

    [***] A CONFIDENTIAL PORTION OF THE MATERIAL HAS BEEN OMITTED AND FILED
            SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.

                                      13

<PAGE>

18.3    The arbitrators shall have the sole authority to decide whether or not
        any Dispute between the parties is arbitrable and whether the party
        presenting the issues to be arbitrated has satisfied the conditions
        precedent to such party's right to commence arbitration.

18.4    The decision of the arbitrators, which shall be in writing and state the
        findings of facts and conclusions of law upon which the decision is
        based, shall be final and binding upon the parties, who shall forthwith
        comply after receipt thereof. Judgment upon the award rendered by the
        arbitrator may be entered by any competent court. Each party submits
        itself to the jurisdiction of any such court, but only for the entry and
        enforcement to judgment with respect to the decision of the arbitrators
        hereunder. The arbitrators shall have the power to grant all legal and
        equitable remedies (including, without limitation, specific performance)
        and award compensatory damages provided by applicable law, but shall not
        have the power or authority to award punitive damages. No party shall
        seek punitive damages in relation to any matter under, arising out of,
        or in connection with or relating to this Agreement in any other forum.

18.5    The parties shall bear their own costs in preparing for and
        participating in the resolution of any Dispute and the costs of the
        arbitrator(s) shall be equally divided between the parties; provided,
        however, that each party shall bear the costs incurred in connection
        with any Dispute brought by such party that the arbitrators determine to
        have been brought in bad faith.

19.     ADDITIONAL WARRANTIES AND REPRESENTATIONS.

19.1    Innovex and Columbia warrant and represent to the other that they have
        the full right and authority to enter into this Master Agreement and
        that there is no impediment that would inhibit their ability to perform
        their respective obligations under this Master Agreement or any Work
        Order.

19.2    Innovex and Columbia agree to perform their obligations hereunder in a
        timely, professional and competent manner.

19.3    Columbia warrants and represents that it possesses good title to, or the
        right to use, any and all trademarks of the Columbia Products, free and
        clear of any claims or encumbrances that would impede the performance by
        either party under the terms of this Agreement or any Work Order. In
        addition, Columbia owns or controls the patents or appropriate licenses
        in connection with all Columbia Products to be involved in the Services,
        and has no knowledge of the existence of any claim or adverse rights
        which would restrict or prevent Columbia or Innovex from performing the
        Services pursuant to this Master Agreement or a Work Order.

19.4    Innovex represents and warrants that there are no collective bargaining
        agreements binding upon Innovex affecting its employees who are or may
        provide Services under this Master Agreement or the Work Order, and that
        there are no pending or threatened organizing efforts affecting the
        same.

    [***] A CONFIDENTIAL PORTION OF THE MATERIAL HAS BEEN OMITTED AND FILED
            SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.

                                      14

<PAGE>

20.     GENERAL PROVISIONS

20.1    This Master Agreement shall be construed, governed, interpreted, and
        applied in accordance with the laws of the State of New Jersey, without
        giving effect to the principles of conflict of laws.

20.2    The rights and obligations of Columbia and Innovex under this Master
        Agreement and any Work Order, which by intent or meaning have validity
        beyond such termination (including, but not limited to, rights with
        respect to confidentiality, mutual indemnification and liability
        limitations) shall survive the termination of this Master Agreement or
        such Work Order.

20.3    This Master Agreement contains the entire understandings of the parties
        with respect to the subject matter herein, and cancels all previous
        agreements (oral and written), negotiations and discussions, dealing
        with the same subject matter. The parties, from time to time during the
        term of this Master Agreement, may modify any of the provisions hereof
        only by an instrument in writing duly executed by the parties.

20.4    References to any Schedule, Appendix, Attachment or Exhibit attached to
        this Master Agreement or any Work Order shall be deemed to incorporate
        the entire contents of the Schedule, Appendix, Attachment or Exhibit by
        reference, as if it were fully set forth in the Master Agreement or Work
        Order to which it is attached.

20.5    No failure or delay on the part of a party in either exercising or
        enforcing any right under this Master Agreement or any Work Order will
        operate as a waiver of, or impair, any such right. No single or partial
        exercise or enforcement of any such right will preclude any other or
        further exercise or enforcement thereof or the exercise or enforcement
        of any other right. No waiver of any such right will have effect unless
        given in a signed writing. No waiver of any such right will be deemed a
        waiver of any other right.

20.6    If any part or parts of this Master Agreement or a Work Order are held
        to be illegal, void or ineffective, the remaining portions of the Master
        Agreement or Work Order shall remain in full force and effect. If any of
        the terms or provisions are in conflict with any applicable statute or
        rule of law, then such term(s) or provision(s) shall be deemed
        inoperative to the extent that they may conflict therewith, and shall be
        deemed to be modified or conformed with such statute or rule of law. In
        the event of any ambiguity respecting any term or terms hereof, the
        parties agree to construe and interpret such ambiguity in good faith in
        such a way as is appropriate to ensure its enforceability and viability.
        Neither party shall assert against the other that the compensation
        arrangement provided in this Agreement or any Work Order is ground for
        voiding the Agreement or Work Order, or rendering the same
        unenforceable.

20.7    The headings contained in this Master Agreement and any Work Order are
        used only as a matter of convenience, and in no way define, limit,
        construe or describe the scope or intent of any section of this Master
        Agreement or such Work Order.

    [***] A CONFIDENTIAL PORTION OF THE MATERIAL HAS BEEN OMITTED AND FILED
            SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.

                                      15

<PAGE>

IN WITNESS WHEREOF, this Master Agreement has been executed by the parties
hereto through their duly authorized officers on the date(s) set forth below.

INNOVEX LP                                          COLUMBIA LABORATORIES, INC.
by: Innovex America Holding
    Company, its General Partner

By:    /S/ Kevin D. Overs                             By:    /S/ Fred Wilkinson
       ------------------                                    ------------------

Name:  Kevin D. Overs                                 Name:  Fred Wilkinson
       --------------                                        --------------

Title: CFO                                            Title: President & CEO
       ---                                                   ---------------

Date:  7/30/02                                        Date:  7/30/02

    [***] A CONFIDENTIAL PORTION OF THE MATERIAL HAS BEEN OMITTED AND FILED
            SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.

                                      16

<PAGE>

                          SALES FORCE WORK ORDER # 8795

                   EFFECTIVE DATE OF WORK ORDER: July 31, 2002

This Sales Force Work Order is entered into between Columbia Laboratories, Inc.,
("Columbia") and Innovex LP ("Innovex"), pursuant to the Master Services
Agreement, having an Effective Date of July 31, 2002, between Columbia and
Innovex, and is subject to all the terms and conditions set forth therein,
except as may be otherwise expressly provided herein.

A.     BRIEF DESCRIPTION OF SALES FORCE PROJECT:
       ----------------------------------------

Sales Force
-----------

A full time 50 - 60 person sales force with 5 managers will be assigned to
selling Procheive 8%, Prochieve 4%, RepHresh, and Advantage-S to a selected list
of approximately [***] gynecologists. Procheive 8% will be in first position,
followed by Prochieve 4%, RepHresh and Advantage-S. The sales force will be on a
four-week cycle (12 cycles a year). Columbia's objective is to maximize the
quality of the calls and to work the office to support the Columbia product
line.

Sales Training
--------------

A modular sales training program is planned. The objective of this first module
is to instruct the representatives in basic reproductive physiology, disorders
associated with infertility and commonly used therapies and procedures. Self
administered exams will be completed by each representative and returned to
confirm that the sales force has basic knowledge of infertility. The second
module will provide product knowledge. A self-administered exam will be returned
to Columbia to confirm that the sales force has basic product knowledge. The
third and last home study module will deal with [***]. A self-administered exam
on this learning will be returned promptly. A national sales meeting will be
held within six weeks of project start. A week prior to the national meeting,
managers will meet to ensure that they are trained to evaluate and assist in the
training of the representatives.

The first order of business at the national sales meeting will be an exam to
demonstrate that the sales force is up to speed, followed by two days extensive
group training, two days of training in smaller groups, and one day designated
for Innovex training regarding personnel management, compensation and benefits
and field administration. Following the national sales meeting, the sales force
should hit the ground running. Through e-mail, Columbia will provide updated
information at a minimum on a monthly basis. Each manager will be responsible
for evaluating each sales person in their region each cycle to ensure they are
properly trained to handle this assignment.

Selling Material
----------------

    [***] A CONFIDENTIAL PORTION OF THE MATERIAL HAS BEEN OMITTED AND FILED
            SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.

                                      17

<PAGE>

Each Visual Aid will be used for [***]cycles meaning that there will be
[***]visual aids per year. When a new visual aid is delivered to the sales
force, it will be accompanied by appropriate training material to ensure that
the representative will use it properly.

As part of their assignment, the sales force will spend time with the practice
nurse to make sure that s/he has the tools to help women follow the regimen. A
special web site will be created to answer questions by the gynecologist, the
staff and women as a means of providing information instantaneously. The sales
force will encourage physicians and their staff to visit it.

The Physician Experience Trial
------------------------------

The Sales Force will be responsible for implementing a physician experience
trial to be designed by Columbia.

B.       PROJECT TEAMS:
         --------------

Columbia Contact Person:  Fred Wilkinson
                          President and CEO
             address:     220 South Orange Avenue
                          Livingston, NJ 07039
             phone:       973-994-3999
             fax:         973-994-3001

Innovex Contact Person:   Bob McGowan
                          VP of Speciality Sales
             address:     10 Waterview Blvd.
                          Parsippany, NJ  07054
             phone:       973-257-4500 x3023
             fax:         814-269-2123

Routine correspondence relevant to the operation of the sales force should be
sent to the above-named contact persons. All notices or similar communications
in regard to the terms or a change of terms of this Work Order are to be sent to
the parties named in the Master Services Agreement - Section 16. Notices.

C.      PROJECT TERM AND KEY DATES:
        ---------------------------

--------------------------------------------------------------------------------
Project Start Date                                      July 31, 2002
--------------------------------------------------------------------------------
District Manager Start Date                             August 8, 2002
--------------------------------------------------------------------------------
Sales Representative Start Date                         August 26, 2002
--------------------------------------------------------------------------------
Home Study                                              August 26 - 31, 2002
--------------------------------------------------------------------------------
Initial In-Class Training Dates                         Sept. 23 - Oct. 1, 2002
--------------------------------------------------------------------------------
Last Sales Representative Field Day                     July 31, 2005
--------------------------------------------------------------------------------
Project End Date                                        July 31, 2005
--------------------------------------------------------------------------------

    [***] A CONFIDENTIAL PORTION OF THE MATERIAL HAS BEEN OMITTED AND FILED
            SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.

                                      18

<PAGE>

"Project Term" shall mean the period of time beginning on the Project Start Date
and ending on the Project End Date.

D.      DEFINITIONS
        -----------

1.      "Day Worked" shall mean a day during which a Sales Representative
        details or presents to Prescribers, or attends scheduled company
        training and/or specifically designated home study. A "Day Worked" by a
        District Manager shall mean a day during which the District Manager
        performs duties and responsibilities described in the Work Order. Days
        Worked shall not include days on leave, holidays, sick days or
        vacations.

2.      "Detail" shall mean an interactive face-to-face contact by a Sales
        Representative with a Prescriber or the Prescriber's legally empowered
        designee, during which a promotional message involving a Prochieve
        Product is given in accordance with the Promotional Program. When used
        as a verb, "detail," "details" and "detailed" shall mean to engage in a
        Detail as defined herein.

3.      "Off-limits Prescriber" shall mean one of the specifically identified
        Prescribers within a Sales Representative's territory that the Sales
        Representative is prohibited from contacting.

4.      "Prescriber" shall mean, in the case of pharmaceutical products,
        physicians and other health care professionals legally authorized to
        write prescriptions for pharmaceutical products and, in the case of
        medical devices, physicians and other health care professionals.

5.      "Presentation" shall mean an interactive face-to-face contact by a Sales
        Representative with a Prescriber or the Prescriber's staff, during which
        a promotional message involving a RepHresh or Advantage-S Product is
        given in accordance with the Promotional Program. When used as a verb,
        "present," "presents" and "presented" shall mean to engage in a
        Presentation as defined herein.

6.      "Product" shall mean, individually and collectively, Prochieve(TM)4%
        Progesterone Gel, Prochieve(TM)8% Progesterone Gel,
        Advantage-S(R)Bioadhesive Contraceptive Gel, and RepHresh Vaginal
        Gel(TM).

7.      "Promotional Expense Budget" shall mean the funding and guidelines for
        use of such funding that are provided by Columbia for use by the Sales
        Force when detailing and presenting Product.

8.      "Promotional Material" shall mean the Product labeling and package
        inserts, sales aids and detailing materials, presentation materials and
        other promotional support items provided by Columbia to Innovex, for use
        in promotion of the Product.

    [***] A CONFIDENTIAL PORTION OF THE MATERIAL HAS BEEN OMITTED AND FILED
            SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.

                                      19

<PAGE>

9.      "Promotional Program" shall mean the marketing plan, strategy and
        promotional message for the Product, which will include use of the
        Promotional Material and the Promotional Expense Budget.

10.     "Referral Message" shall mean the promotional message, as provided by
        Columbia to Innovex from time to time, that any patient who has not
        become pregnant after three (3) cycles of treatment using clomiphene
        citrate together with 8% progesterone gel should seek care of an
        assisted reproductive technology specialist for further treatment.

11.     "Sales Force" shall mean the Sales Representatives, District Managers,
        Regional Sales Managers and National Sales Manager, individually and as
        a group, that have been assigned to deliver Details and Presentations of
        the Product in accordance with the terms of this Agreement.

12.     "Sales Representative" shall mean an Innovex employee who has been
        trained and equipped to detail and present to Prescribers.

13.     "Target Prescriber" shall mean one of the specifically identified
        Prescribers within a Sales Representative's territory to be detailed and
        presented to by the Sales Representative.

14.     "Territory" shall mean the United States and Puerto Rico. In connection
        with an individual Sales Representative, the territory shall be the
        geographic area assigned to the individual Sales Representative.

E.      INNOVEX RIGHTS, RESPONSIBILITIES AND OBLIGATIONS
        ------------------------------------------------

1.      Sales Force. The Sales Force will be composed of the following Innovex
        employees:

-------------------------------------------------------------------------------
   Number                                    Position Title
-------------------------------------------------------------------------------
    55                  Sales Representatives
-------------------------------------------------------------------------------
     5                  District Managers
-------------------------------------------------------------------------------

        In addition, Innovex will provide appropriate management oversight of
        the Sales Force, including that of a National Sales Manager. Columbia
        may request that Innovex provide additional Sales Representatives, by
        submitting a written request in substantially the form attached hereto
        as Exhibit 1, ("Additional Sales Representative Request Form"). As the
        total number of Sales Representatives increases for the Sales Force,
        additional District Managers will also be increased in order to maintain
        a maximum ratio of District Managers to Sales Representatives of 1:12.

2.      Recruitment. Innovex shall be responsible for recruitment and
        re-recruitment (replacement) of the Sales Representatives and District
        Managers in accordance with the Sales Force Qualifications described
        below. Innovex shall be responsible for the cost of recruitment,
        background checks and drug screens. If Columbia elects to participate in
        the final selection of members of the Sales Force, Columbia shall
        approve or disapprove qualified candidates

    [***] A CONFIDENTIAL PORTION OF THE MATERIAL HAS BEEN OMITTED AND FILED
            SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.

                                      20

<PAGE>

        within five (5) business days after each qualified candidate is
        submitted to Columbia for final selection. A "qualified candidate" must
        meet the Sales Force Qualifications.

3.      Sales Force Qualifications. Innovex will exercise best efforts to
        recruit from a diverse candidate base. A qualified candidate for Sales
        Representatives shall meet the following minimum qualifications:
        four-year college degree (B.A., B.S. or equivalent); minimum one year
        outside sales experience, preferably within pharmaceuticals and women's
        health. At least 40% of Sales representatives shall have a minimum of
        one year of pharmaceutical sales experience, of which at least 30% shall
        be in women's health. A qualified candidate for District Manager shall
        meet the following minimum qualifications: four-year college degree
        (B.A., B.S. or equivalent); minimum 2 years outside sales experience,
        minimum one year previous management experience in pharmaceutical sales.

4.      Position Descriptions and Duties. Innovex shall manage, supervise and
        evaluate the performance of the National Sales Manager, District
        Managers and Sales Representatives in accordance with the
        responsibilities and duties identified below. All Sales Force employees
        shall demonstrate the following: work ethic and integrity; planning,
        organizing and territory management skills; strong interpersonal skills;
        excellent communication skills; critical thinking and analysis; problem
        solving; decisiveness; sound judgment; Columbia-focused selling skills;
        basic computer skills; ability to listen and learn.

        SALES REPRESENTATIVES
          .  Generate sales within an assigned territory
          .  Maintain and update current and prospective target physician
             profiles
          .  Avoid all contact whatsoever with Off-limits Prescribers
          .  Keep current with market knowledge and competitive products
          .  Avoid any comparison or reference to Crinone(R)(progesterone gel)
             products marketed by Serono, Inc.
          .  Maintain a professional image for Columbia and Columbia Products
          .  Participate in all training and sales meetings
          .  Plan and organize territory to meet sales and call targets
          .  Make sales presentations (Details and Presentations) - individual,
             one-on-one, in-services
          .  Deliver the Referral Message with each sales presentation (Detail)
             of Prochieve 8% (progesterone gel)
          .  Comply with PDMA
          .  Make complete, accurate and timely submission of all time-keeping,
             call activity and expense reports
          .  Compliance with Promotional Program, and proper use of Promotional
             Materials and Promotional Expense Budgets
          .  Participate or coordinate Lunch & Learns, dinner programs, weekend
             events, as appropriate
          .  Have appropriate interaction with co-promotional partners or
             counterparts

    [***] A CONFIDENTIAL PORTION OF THE MATERIAL HAS BEEN OMITTED AND FILED
            SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.

                                      21

<PAGE>

        NATIONAL SALES MANAGER, DISTRICT MANAGERS
          .  Recruit, interview and select Sales Representatives and subordinate
             managers
          .  Handle 120 day and annual performance review, personnel issues,
             discipline and termination of Sales Representatives and subordinate
             managers
          .  District Managers shall make regular field visits: to develop and
             motivate Sales Representatives for attainment of sales objectives;
             to assess and monitor field activity and work schedules; to monitor
             and manage field reporting by Sales Representatives, including call
             reporting.
          .  Communicate with Columbia field/regional managers on regular and
             timely basis
          .  Assist with the planning and delivery of training, and periodic
             sales meetings
          .  Review and approve expense reports; monitor compliance with expense
             policies.
          .  Monitors compliance with Promotional Program, and proper use of
             Promotional Materials and Promotional Expense Budgets
          .  Monitors compliance with Off-limits Prescriber restrictions
          .  Monitors compliance with Crinone(R) products restrictions
          .  Monitors delivery of the Referral Message
          .  Monitors compliance with PDMA
          .  Monitors time-keeping and attendance

5.      Sales Force Compensation; Benefits. Innovex shall compensate the Sales
        Force employees with a combination of salary and variable incentive
        (bonus). Innovex shall establish a target average salary and salary
        matrix, which recognizes greater experience and training, and preferred
        selection criteria. The terms and conditions of a variable incentive
        compensation plan ("Incentive Plan") shall be mutually determined by
        Innovex and Columbia, including eligibility criteria and performance
        targets. The plan may also include incentive awards such as trips and
        prizes. Innovex shall administer the Incentive Plan, determine
        eligibility and pay the incentive compensation and awards, in accordance
        with the Incentive Plan. Sales Force employees shall be eligible to
        receive an auto allowance, and shall be entitled to participate in the
        Innovex employee benefit plans for health and dental care, 401K,
        employee stock purchase and stock ownership plans, in accordance with
        company eligibility criteria.

6.      Training and Periodic Sales Meetings. Innovex shall facilitate the
        participation of the Sales Force in Columbia's initial training of the
        Sales Force, backfill training of replacement District Managers and
        Sales Representatives and all follow-up training, including periodic
        sales meetings. Columbia may request Innovex's participation in the
        delivery of training and Innovex will provide such services on a time
        and materials basis as the parties may agree. In all cases, Innovex
        shall monitor and observe all Columbia training. Innovex may have Sales
        Force Members participate in the Innovex Leadership Development Program.

7.      Promotional Activities. Innovex shall be responsible for managing and
        monitoring the promotional activities of the Sales Force, in strict
        adherence to the Promotional Program and using only the Promotional
        Materials provided by Columbia. Sales Representatives shall not be
        permitted to develop, create or use any other promotional material or
        literature in connection with the promotion of the Product. The Sales
        Representatives will be required to immediately cease the use of any
        Promotional Materials when instructed to do so by

    [***] A CONFIDENTIAL PORTION OF THE MATERIAL HAS BEEN OMITTED AND FILED
            SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.

                                      22

<PAGE>

        Columbia. Innovex shall monitor that Promotional Materials are not
        changed, (including, without limitation, by underlining or otherwise
        highlighting any text or graphics or adding any notes thereto) by the
        Sales Representatives. Sales Representatives shall be required to limit
        their statements and claims regarding the Product, including as to
        efficacy and safety, to those which are consistent with the Product
        labels, package inserts and Promotional Materials. The Sales
        Representatives shall not be permitted to add, delete or modify claims
        of the efficacy or safety in the promotion of the Product, nor shall the
        Sales Representatives be permitted to make any untrue or misleading
        statements or comments about the Products or any Columbia competitors or
        competitor products. Sales Representatives shall be prohibited from (i)
        contacting Off-limits Prescribers and (ii) making comparisons or
        references to Crinone(R)products.

8.      Project Reports. Innovex shall provide Columbia a monthly Project
        report, which shall include: (i) headcount, reported nationally, by
        region/district; vacancy rates, turnover, personnel transfers to
        Columbia, status of recruitment/hiring; (ii) Project status, milestones,
        and progress toward achieving objectives; (iii) financial
        accountability, tracking expenses against budget; and (iv) if required
        by the Work Order, call reporting and sample accountability.

9.      Reporting by Sales Representatives. Sales Representatives shall be
        required to report all field activities and expenditures in a manner
        that is timely, accurate and honest, and in accordance with policies and
        procedures for the applicable reporting systems. Innovex District
        Managers shall routinely reinforce the importance of compliance with the
        reporting guidelines and policies (e.g. sample accountability, call
        reporting, promotional budget expenditures, travel expenses). Newly
        hired Sales Representatives shall receive training on the reporting
        systems, guidelines and policies during the initial sales training
        program

10.     ITMS and Call Reporting. Innovex shall provide the Innovex Territory
        Management System, including automated call reporting functions. Innovex
        shall equip the Sales Force with computer hardware and software, and
        shall bear the cost of database and system administration, licenses,
        access to data/replication lines, help desk support, and training of the
        Sales Force in proper use of the computers and software.

11.     Management and Discipline of the Sales Force. Innovex shall be
        responsible to manage the Sales Force. Innovex has sole authority to
        remove employees from the Sales Force. In conformance with Innovex
        policy, Innovex shall provide appropriate employee counseling and
        discipline, up to and including termination, on its own initiative and
        upon the reasonable request of Columbia, to Sales Force members who
        violate employment rules and who are otherwise under performing their
        job responsibilities. Innovex will promptly follow-up on any reports
        made by Columbia of Sales Force member non-compliance and will apply
        such counseling or discipline as may be warranted in Innovex's judgement
        consistent with Innovex's prior employment practices.

12.     Business Cards; Detail Bags. Innovex shall supply the Sales Force with
        business cards, the content of which shall be subject to approval by
        Columbia, such approval not to be

    [***] A CONFIDENTIAL PORTION OF THE MATERIAL HAS BEEN OMITTED AND FILED
            SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.

                                      23

<PAGE>

        unreasonably withheld. Innovex shall supply the Sales Force with detail
        bags. Columbia shall provide Innovex with camera ready artwork of
        Columbia's logo or other content Columbia wishes to include on the
        business cards.

F.      COLUMBIA RIGHTS, RESPONSIBILITIES AND OBLIGATIONS
        -------------------------------------------------

1.      Promotional Program and Promotional Materials. Columbia shall be
        responsible for providing a Promotional Program, Promotional Materials
        and Promotional Expense Budget that (i) will not involve the counseling
        or promotion of a business arrangement that violates federal or state
        law; (ii) will be in compliance with the AMA Guidelines on Gifts to
        Physicians from Industry; and (iii) shall not require or encourage the
        Sales Representatives to offer, pay, solicit or receive any remuneration
        from or to Prescribers to induce referrals or purchase of Columbia
        Product. Columbia shall be responsible for providing written guidelines
        for proper use of the Columbia's Promotional Expense Budget.

2.      Training and Periodic Sales Meetings.
        Columbia shall be responsible for the following:
        .  Programming, materials and facilities for initial Sales Force
           training. The initial training agenda shall include one day
           designated for Innovex training regarding personnel management,
           compensation and benefits and field administration.
        .  Programming, materials and facilities for periodic sales meetings or
           product launch meetings as designated by Columbia.

        Any reasonable, documented and approved expenses incurred by Innovex in
        conjunction with Sales Force training shall be a Pass-Through Expense to
        Columbia.

3.      Sales Data. Columbia shall be solely responsible for obtaining historic
        and ongoing sales data regarding Columbia Products. Columbia shall be
        solely responsible to pay any applicable per representative fee required
        by any third party, except for the fee imposed by the American Medical
        Association. Upon execution of this Agreement, Innovex will provide
        Columbia with the historic data used to size and structure the Sales
        Force. Columbia shall provide Innovex with the data reasonably necessary
        to maintain Sales Force effectiveness including but not limited to, (i)
        Exponent sales/total Rx data by territory, district, region, and nation;
        and (ii) Early view by territory.

4.      Sales Force Travel Expenses. Columbia shall be responsible for all Sales
        Force travel, lodging and meal expenses, when necessary, documented, and
        actually incurred by the Sales Force in the amounts authorized in the
        annual Sales Force travel expense budget set forth on Exhibit 2 attached
        hereto. Columbia shall have no responsibility for, or obligation to pay
        for, travel expenses exceeding the budget without Columbia's consent.

5.      No Recruitment. Through the Project End Date and for one year
        thereafter, neither party shall attempt to actively recruit or solicit
        any personnel of the other party without the prior written consent of
        such party; except as otherwise provided herein and provided that,
        notwithstanding the foregoing, a party shall be permitted to engage in
        general recruitment

    [***] A CONFIDENTIAL PORTION OF THE MATERIAL HAS BEEN OMITTED AND FILED
            SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.

                                      24

<PAGE>

        through advertisements or recruiting through head-hunters so long as
        Innovex employees and personnel are not specifically targeted.

6.      Transfer of Ancillary Services. On or after August 19, 2003, Columbia
        may, upon 60 days prior notice to Innovex, assume direct responsibility
        for call reporting, sample accountability and reporting, and computers
        and support services related to the Sales Force.. Should Columbia assume
        such services, it shall remain responsible to pay the monthly fee set
        forth in paragraphs (G)(4)&(5) of this Work Order.

G.      FEES AND PASS-THROUGH EXPENSES
        ------------------------------

1.      Daily Fees. Columbia shall pay Innovex a Daily Fee for each Day Worked
        by Sales Representatives and Field Managers during the Project Term and
        thereafter if required for Project close-out. The Daily Fees and total
        estimated Daily Fees during the first year of the Project Term are
        stated in the following table:

<TABLE>
<CAPTION>
--------------------------------------------------------------------------------------------------------------------
     Sales Force Positions           Number      Daily Rate      Estimated       Estimated          Estimated
                                                                Days Worked      Total Days         Total Fees
                                                                                   Worked
--------------------------------------------------------------------------------------------------------------------
     <S>                               <C>         <C>             <C>             <C>                <C>
     Sales Representatives             55          $[***]          [***]           [***]              $[***]
--------------------------------------------------------------------------------------------------------------------
       District Managers               5           $[***]          [***]           [***]              $[***]
--------------------------------------------------------------------------------------------------------------------
                                                                   Estimated Total Fees               $[***]
--------------------------------------------------------------------------------------------------------------------
</TABLE>

        Effective August 19, 2003, these Daily Rates may be increased by up to
        [***]%. Effective August 19, 2004, the then effective Daily Rates may be
        increased by up to [***]%.

2.      Take-On Fee.
        -----------

        a.  Individual Sales Force Members. Innovex shall charge Columbia a fee
            for each Sales Force member that becomes employed by Columbia or an
            affiliate during the Project Term, or six months thereafter if
            Columbia does not exercise its rollover rights with respect to such
            member under paragraph (g)(2)(b); provided however, that Columbia
            may only hire a Sales Force member during such period upon providing
            Innovex 15 days notice of Columbia's desire to so hire and, in the
            case of Sales Representatives only upon Innovex express consent. For
            each hire, Columbia shall pay Innovex the following: during the
            first, second, and third years of the term, an amount equal to
            [***]%,[***]%, and [***]%, respectively of the employee's Innovex
            annual salary. These amounts shall be included in Innovex's regular
            invoicing.

            (i)  Use of Take-on Fees. Innovex, in its sole discretion, may make
                 the fees paid by Columbia under paragraph G(2)(a) available for
                 the Sales Force retention initiatives as may be warranted and
                 prudent during the Project Term. The Steering Committee may
                 make recommendations to Innovex on such expenditures.

    [***] A CONFIDENTIAL PORTION OF THE MATERIAL HAS BEEN OMITTED AND FILED
            SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.

                                      25

<PAGE>

        b.  Sales Force Rollover. Columbia may hire directly [***]% or more of
            the Sales Force contemporaneously with the Project End Date by
            providing Innovex 90 days notice and without any payment to Innovex,
            whatsoever.

3.      Incentive Plan Administration. Columbia shall pay Innovex an amount
        equal to (i) the amount of all non-salary compensation earned by Sales
        Force members in accordance with the terms of the Incentive Plan or
        otherwise requested by Columbia; and (ii) an amount equal to [***]% of
        such compensation for Innovex's employer costs (payroll taxes,
        benefits).

4.      ITMS Fees. For Innovex's provision of ITMS Services as set forth in
        paragraph E(10) of this Work Order, Columbia shall pay a monthly service
        fee in the amount of $[***] per Sales Representative, District Manager
        and the National Sales Manager through the Project End Date.

5.      Payment Schedule. Innovex shall send Columbia an estimated cost for each
        month ten (10) days in advance, including all incentive compensation and
        related employer costs. Columbia shall pay the estimated monthly charge
        on the first day of the month by wire transfer to the account designated
        by Innovex. At the end of each calendar month Innovex shall provide
        Columbia a list of the billable Sales Force personnel and the total
        number of Days Worked multiplied by the respective Daily Fee rate and
        all Fees, Take-on Fees and Pass-Through Expenses. Innovex shall add any
        underpayment to, and deduct any overpayment from, the next estimate sent
        to Columbia. The parties shall use good faith efforts to reconcile any
        disputed amount as soon as practicable. One half of any amount in
        dispute for more than 30 days shall be credited against the next
        estimate (provided the amount in dispute was paid by Columbia based on a
        previous estimate) sent to Columbia and remain as a credit until the
        dispute is resolved.

6.      Initial Payment. Upon the execution of this Agreement, Columbia shall
        make an immediate payment to Innovex in the amount of $ [***], to be
        credited against the first estimated payments due to Innovex.

7.      Changes in Scope; Additional Services. All prices and costs contained in
        this Work Order are subject to revision as needed to reflect changes in
        the scope of services being provided by Innovex. Additional services
        will be provided at Innovex's normal and customary rates.

8.      Expense Allocation Chart. The financial responsibility of Innovex and
        Columbia for expenses and costs of Sales Force operation shall be
        allocated in accordance with the terms of this Work Order, which are
        summarized for illustrative purposes in the "Sales Force Expense
        Allocation" chart (Attachment A).

H.      ADDITIONAL TERMS
        ----------------

1.      Steering Committee. Columbia shall make all decisions with respect to
        the strategy for the marketing and Promotion of the Products. However,
        other issues may arise under the terms of this Agreement or between the
        parties while operating under this Agreement which are

    [***] A CONFIDENTIAL PORTION OF THE MATERIAL HAS BEEN OMITTED AND FILED
            SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.

                                      26

<PAGE>

        appropriate for consultation between the parties to ensure maximum
        productivity of the Sales Force, including, but not limited to, the
        establishment of work rules or the response to greater than expected
        Sales Force turnover and other changing market conditions. The parties
        shall, therefore, establish a Steering Committee, chaired by Columbia
        and consisting of up to three (3) members from each party. The
        chairperson's duties shall include site selection, logistics, agenda and
        facilitation; provided however, that a Innovex Committee member may
        submit agenda items to the Chair and such items shall be included in the
        next regular meeting of the Steering Committee. Each member of the
        Committee shall be an employee or member of the Board of Directors of
        the party that appointed such member. Initial appointments shall be made
        within fourteen (14) days of the date of this Agreement. A member of the
        Committee may be removed at any time, with or without cause, by the
        party that appointed such member. The Committee shall meet each quarter,
        or otherwise at the call of the chairperson to review, coordinate, and
        discuss issues regarding the Promotional Program. In addition, the
        Committee shall review and resolve issues pertaining to this Agreement.
        The members of the Committee will use reasonable efforts to reach
        consensus on all decisions.

In Witness Whereof, Columbia and Innovex have caused this Work Order # 8795 to
be duly executed on their behalf by their authorized representatives and made
effective as of Effective Date of Work Order appearing above.

ACCEPTED AND AGREED TO BY:

COLUMBIA LABORATORIES, INC.                       INNOVEX LP
                                                  by: Innovex America Holding
                                                   Company, its General Partner

/S/ Fred Wilkinson                                /S/ Kevin D. Overs
------------------                                ------------------
By: Fred Wilkinson                                By: Kevin D. Overs
Title: President & CEO                            Title: CFO
Date: 7/30/02                                     Date: 7/30/02

    [***] A CONFIDENTIAL PORTION OF THE MATERIAL HAS BEEN OMITTED AND FILED
            SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.

                                      27

<PAGE>

                     ATTACHMENT A TO SALES FORCE WORK ORDER
                         SALES FORCE EXPENSE ALLOCATION
                         ------------------------------
                                    JULY 2002
                                 PROJECT # 8795

<TABLE>
<CAPTION>
----------------------------------------------------------------------------------------------------------------------------
                               Category                                      Innovex         PassThrough        Columbia
                                                                             Direct           Expenses           Direct
                                                                            Expenses                            Expenses
----------------------------------------------------------------------------------------------------------------------------
<S>                                                                             <C>               <C>              <C>
Salary, including payroll taxes, for Sales Representatives, District            X
Managers, National Sales Manager
----------------------------------------------------------------------------------------------------------------------------
Incentive compensation (bonus) for Sales Representatives, District                                X
Manager, and National Sales Manager, plus [***]%
----------------------------------------------------------------------------------------------------------------------------
Benefits package, including (401k), ESOP, ESPP, medical, dental,                X
Rx, vacation, holidays
----------------------------------------------------------------------------------------------------------------------------
Auto Costs in territory, including monthly allowance, mileage                   X
reimbursement, parking and tolls.
----------------------------------------------------------------------------------------------------------------------------
Basic Business Expenses in territory, including phone,                          X
paper supplies, postage and voice mail.
----------------------------------------------------------------------------------------------------------------------------
Business Cards & Detail Bags                                                    X
----------------------------------------------------------------------------------------------------------------------------
Call Reporting ; ITMS                                                           X
----------------------------------------------------------------------------------------------------------------------------
Computers for Sales Representatives, including software, helpdesk               X
support, data/replication lines
----------------------------------------------------------------------------------------------------------------------------
Computers for DMs, NSM, including software, helpdesk support,                   X
data/replication lines
----------------------------------------------------------------------------------------------------------------------------
Infrastructure support (operations, HR, finance, legal)                         X
----------------------------------------------------------------------------------------------------------------------------
Liability Insurance: employment, workers comp, E & O, CGL, auto                 X
----------------------------------------------------------------------------------------------------------------------------
Recruitment and re-recruitment, includes drug screens, background               X
and motor vehicle checks
----------------------------------------------------------------------------------------------------------------------------
Meetings: Columbia national, regional and district meetings; product                              X
launches
----------------------------------------------------------------------------------------------------------------------------
Promotional Expense Budget (access money)                                                         X
----------------------------------------------------------------------------------------------------------------------------
Promotional Program and Promotional Materials (sales aids)                                                         X
----------------------------------------------------------------------------------------------------------------------------
Promotional marketing expenses, including sales data                                                               X
----------------------------------------------------------------------------------------------------------------------------
Training program, materials and facilities; initial and follow-up                                                  X
----------------------------------------------------------------------------------------------------------------------------
Travel Expenses (air, hotel, meals, T&E) for Sales Reps, District                                 X
Managers, National Sales Manager                                                                  X
*Interviewing                                                                                     X
*Training                                                                                         X
*Territory travel for field management purposes                                                   X
----------------------------------------------------------------------------------------------------------------------------
</TABLE>

    [***] A CONFIDENTIAL PORTION OF THE MATERIAL HAS BEEN OMITTED AND FILED
            SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.

                                      28

<PAGE>

                       EXHIBIT 1 TO SALES FORCE WORK ORDER
                  ADDITIONAL SALES REPRESENTATIVE REQUEST FORM

This Request for Additional Sales Representative is issued pursuant to the
Master Sales Services Agreement between Columbia and Innovex LP, dated as of
July 31, 2002, and Work Order/Sales Force # 8795, dated as of July 31, 2002.

<TABLE>
<CAPTION>
--------------------------------------------------------------------------------------------------------
PART 1                                   To be completed by Columbia
                                         Attach any relevant, helpful information
--------------------------------------------------------------------------------------------------------
<S>                                      <C>
NUMBER OF SALES REPRESENTATIVES
REQUESTED
--------------------------------------------------------------------------------------------------------

TERRITORY LOCATION(S)

--------------------------------------------------------------------------------------------------------

REQUESTED START DATE

--------------------------------------------------------------------------------------------------------

AUTHORIZED COLUMBIA REPRESENTATIVE       Signature: ____________________________________
SUBMITTING REQUEST                       Name:
                                         Title:
                                         Date:
                                         Phone:
                                         Fax:

--------------------------------------------------------------------------------------------------------
PART 2                                   To Be Completed by Innovex
                                         Innovex shall respond within ten (10) business days after
                                         receipt of the Additional Sales Representatives Request.
--------------------------------------------------------------------------------------------------------

This Additional Sales Representative     Request is Accepted, and Recruitment shall begin immediately:
Request Form was Received by Innovex
on the following date:                   ____________________________________________
                                         (sign and date)
         _____________________           Contact Person:
                                         Phone:
--------------------------------------------------------------------------------------------------------

                                         Request is Not Accepted (identify above
                                         information which must be clarified or
                                         changed before Request may be accepted
                                         by Innovex):

                                         ______________________________________________________________
                                         (sign and date)
                                         Contact Person:
                                         Phone:
--------------------------------------------------------------------------------------------------------
</TABLE>

    [***] A CONFIDENTIAL PORTION OF THE MATERIAL HAS BEEN OMITTED AND FILED
            SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.

                                      29

<PAGE>

                       EXHIBIT 2 TO SALES FORCE WORK ORDER
                              ANNUAL TRAVEL BUDGET

7/31/02 - 9/17/03 ("Year One"):

$[***] for Initial Sales Force Training

$[***] for POA Meetings and Field Based Travel

9/18/03 - 9/17/04 ("Year Two"):

Year One budget plus [***]%

9/18/04 - 10/14/05

Year Two budget plus [***]%

    [***] A CONFIDENTIAL PORTION OF THE MATERIAL HAS BEEN OMITTED AND FILED
            SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.

                                      30

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00042-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00042-of-00352.parquet"}]]